Feline Calicivirus

Overview and Taxonomy of Feline Calicivirus

Historical Context and Clinical Significance

Feline calicivirus (FCV) represents one of the most clinically significant and globally prevalent viral pathogens affecting domestic and wild felids, first isolated in 1957 from the gastrointestinal tract of cats in New Zealand [22]. Since its initial recognition, FCV has emerged as a primary etiological agent of feline upper respiratory tract disease (URTD), alongside feline herpesvirus type 1 (FHV-1), and is responsible for a substantial proportion of infectious oronasal disease presentations in veterinary practice worldwide [3, 22]. The virus is a member of the family Caliciviridae, a diverse group of small, non-enveloped, positive-sense single-stranded RNA viruses that include important human and animal pathogens such as norovirus, sapovirus, and rabbit hemorrhagic disease virus [4, 6]. FCV is particularly noteworthy as one of the few caliciviruses that propagates efficiently in cell culture, rendering it an indispensable surrogate model for studying the biology of non-cultivable human caliciviruses, particularly human norovirus [6, 10, 12, 13].

The taxonomic classification of FCV places it firmly within the genus Vesivirus, a designation that distinguishes it from other calicivirus genera based on genomic organization, replication strategy, and the presence of a unique leader of the capsid (LC) protein, a feature exclusive to vesiviruses [27, 46]. This genus also includes vesicular exanthema of swine virus and other marine mammal caliciviruses, though FCV remains the most extensively characterized member due to its veterinary importance and experimental tractability [4, 6]. The significance of FCV extends beyond its role as a respiratory pathogen; it is associated with a remarkably broad spectrum of clinical manifestations, ranging from subclinical infections and mild oral ulceration to severe, life-threatening virulent systemic disease (VSD), highlighting the complex interplay between viral genetic diversity and host factors [3, 4, 7].

Genomic Architecture and Structural Organization

The FCV genome is a single-stranded, positive-sense RNA molecule of approximately 7.7 kilobases, organized into three primary open reading frames (ORFs) flanked by 5′ and 3′ untranslated regions (UTRs) [4, 36, 47]. The genomic organization of FCV is a defining characteristic of the Vesivirus genus and is critical for understanding its replication cycle, pathogenesis, and evolutionary potential. ORF1 occupies the 5′ proximal region of the genome and encodes a large polyprotein that is co- and post-translationally cleaved by the viral protease (NS6/7) into several non-structural proteins essential for replication, including p30, p32, p39, the helicase, the VPg (viral protein genome-linked), the protease-polymerase (PP), and the RNA-dependent RNA polymerase (RdRp) [4, 16, 37]. These non-structural proteins orchestrate viral RNA synthesis, modulate host cellular environments, and subvert innate immune responses, with p30, p32, and p39 having been identified as inducers of autophagy and p30 as a direct antagonist of type I interferon signaling [16, 41].

ORF2, situated downstream of ORF1, encodes the major capsid protein precursor, VP1, which is cleaved by the viral protease to release the mature capsid protein and the LC protein [46]. The VP1 protein is the primary antigenic determinant of FCV and the principal target of neutralizing antibody responses, making it the focus of vaccine development and molecular epidemiological studies [8, 14, 39]. The capsid is composed of 180 copies of VP1 arranged in an icosahedral T=3 symmetry, with each subunit organized into three distinct domains: the shell (S) domain, which forms the inner core of the capsid; the protruding (P) domain, which is further divided into the P1 and P2 subdomains; and the hypervariable E region, located within the P2 subdomain, which constitutes the most antigenically diverse portion of the protein [8, 39, 42]. The E region, spanning approximately amino acid residues 425–457, is the dominant neutralizing epitope region and is under intense positive selection pressure, driving the antigenic diversity observed among field strains [14, 39, 42]. ORF3, the smallest of the three reading frames, encodes the minor capsid protein VP2, which has recently been demonstrated to play a critical role in genome release by functioning as a pore-forming protein that mediates the puncturing of endosomal membranes during viral entry [6].

The Leader of the Capsid Protein and Its Unique Functions

A distinguishing feature of the Vesivirus genus, including FCV, is the production of an LC protein, which is translated as an N-terminal extension of VP1 and subsequently cleaved to function as a separate entity [27, 44, 46]. The LC protein is not present in other calicivirus genera, making it a unique molecular hallmark of vesiviruses. Initially thought to be dispensable for replication, the LC protein is now recognized as a multifunctional virulence factor that contributes to apoptosis induction, immune evasion, and viral pathogenesis. Barrera-Vázquez et al. demonstrated that the LC protein downregulates the anti-apoptotic proteins survivin and XIAP, leading to mitochondrial damage, caspase-3 activation, and the induction of intrinsic apoptosis, a process that facilitates viral dissemination while simultaneously limiting the host's ability to mount an effective immune response [44]. Furthermore, Peñaflor-Téllez and colleagues characterized the LC protein as a viroporin, demonstrating its ability to oligomerize through disulfide bonds, induce osmotic stress in bacteria, and permeabilize membranes, characteristics consistent with antimicrobial peptide-like activity [27]. The LC protein’s capacity to form pores and trigger apoptosis underscores its central role in the FCV life cycle and positions it as a potential target for antiviral intervention.

Genetic Diversity, Quasispecies Dynamics, and Recombination

FCV is an RNA virus with a high mutation rate, estimated at approximately 10⁻³ to 10⁻⁵ substitutions per nucleotide per replication cycle, which is characteristic of RNA-dependent RNA polymerases lacking proofreading activity [3, 4]. This genetic plasticity, combined with a large population size and rapid replication kinetics, allows FCV to exist as a complex quasispecies within individual hosts, enabling rapid adaptation to selective pressures such as immune responses, antiviral drugs, and environmental changes [4, 22]. The hypervariable E region of the VP1 gene, in particular, exhibits extensive sequence heterogeneity, with amino acid identities as low as 50–60% among field isolates, a diversity that poses significant challenges for vaccine design and cross-protection [14, 33, 43]. The E region is the primary target of neutralizing antibodies, and mutations within this region can lead to antigenic drift, allowing emerging variants to escape vaccine-induced immunity and re-infect previously exposed or vaccinated cats [5, 43].

Phylogenetic analyses based on complete VP1 sequences have consistently demonstrated that FCV field strains segregate into two major genotypes, designated GI and GII, though some studies have proposed additional sub-clades or groups based on whole-genome analysis [5, 14, 24, 32]. The classification into GI and GII is supported by robust phylogenetic bootstrapping and distinct amino acid signatures within the capsid protein, with GI strains being globally distributed and GII strains exhibiting a more restricted geographic distribution, predominantly isolated from Asia [14]. Yang et al., in a comprehensive analysis of 105 FCV VP1 sequences, demonstrated that while GI strains circulate worldwide, all GII strains identified to date originated from Asia, suggesting a potential geographical bottleneck or founder effect [14]. Cao et al. further refined this classification by analyzing 26 Chinese isolates, identifying 10 GI and 16 GII strains, and revealing that Chinese isolates cluster into distinct groups (C and D) that are evolutionarily distant from the commonly used vaccine strain FCV-255 [18, 32]. The co-circulation of both genotypes in endemic regions, as documented in studies from China [24, 26, 32], Thailand [9], and Korea [36], highlights the dynamic evolutionary landscape of FCV and the potential for recombination events that can generate novel strains with altered virulence and antigenicity.

Recombination is a major driver of FCV genetic diversity and has been increasingly recognized as a mechanism for the emergence of virulent variants. Multiple studies have identified inter- and intra-genotypic recombination events within the FCV genome, particularly at the ORF1-ORF2 junction and within the protease-polymerase region [2, 20, 36]. Wang et al. reported the first recombinant strain of FCV in Beijing, originating from recombination between two earlier strains from 2019 [2]. Liu et al. isolated a recombinant strain (qd/2019/china) from Qingdao, China, which resulted from a recombination event between CH-JL4 and HRB-SS, with the recombinant region spanning nucleotides 3,821–5,301 within the PP region [20]. Lee et al. identified an intergenic recombination in a Korean FCV strain (14Q315) associated with hemorrhagic-like disease, demonstrating that a UTCVM-H1-like virus had been introduced into Korea and recombined with endemic Korean strains, potentially contributing to increased pathogenicity [36]. The high frequency of recombination, coupled with rapid mutation rates, ensures that FCV populations remain genetically fluid, capable of generating new antigenic variants that can overcome population immunity and complicate disease control efforts.

Receptor Usage, Cellular Tropism, and Entry Mechanisms

The cellular entry of FCV is mediated by the interaction between the capsid protein VP1 and the feline junctional adhesion molecule-A (fJAM-A), a transmembrane glycoprotein belonging to the immunoglobulin superfamily that is expressed on epithelial and endothelial cells [2, 6, 42]. The E region of VP1 is directly involved in receptor binding, and the conformational flexibility of this region is essential for triggering post-binding events that lead to genome release [6, 42]. After receptor engagement, the virus is internalized via clathrin-mediated endocytosis, and the acidic environment of early endosomes induces conformational changes in the capsid that facilitate the dissociation of VP2 and the formation of a portal-like structure through which the genomic RNA is released into the cytoplasm [6]. Sun et al. elegantly demonstrated that VP2, a protein rich in hydrophobic N-terminal residues, functions as the pore-forming protein that punctures the endosomal membrane, and mutation of these hydrophobic residues significantly reduces genome release efficacy [6]. This receptor-dependent, low-pH-triggered entry mechanism is a defining feature of FCV infection and is conserved across diverse strains, though variations in receptor affinity or post-binding events may contribute to differences in tissue tropism and virulence between classical URTD strains and VS-FCV variants [42].

Brunet et al. employed multiple correspondence analysis of amino acid properties within the E region and identified seven residues that statistically differentiate classical from virulent systemic FCV strains, many of which map to the receptor-binding interface and may influence conformational changes required for efficient membrane penetration [42]. These findings suggest that while fJAM-A serves as the primary entry receptor for all FCV strains, subtle differences in capsid-receptor interactions or post-binding dynamics may dictate the ability of VS-FCV strains to infect a broader range of cell types, including vascular endothelial cells, leading to the systemic dissemination and vascular compromise characteristic of VSD [11, 21, 42].

Epidemiology, Host Range, and Transmission Dynamics

FCV is endemic in feline populations worldwide, with prevalence rates varying widely depending on the population studied, geographic region, sampling methodology, and diagnostic techniques employed. Recent epidemiological surveys have reported FCV positivity rates of 31.3% in Beijing [2], 26% in Kunshan [5], 28.9% in Guangdong [23], 41.9% in Nanjing [28], 43.0% in Hangzhou [33], 25.7% in the Moscow metropolitan area [30], 46.7% in Thailand [9], and 26.8% in a recent Chinese multi-region study [1]. A multi-national European cross-sectional study involving six countries reported an overall prevalence of 9.2% in cats presenting to veterinary practices, with higher rates observed in multi-cat households and shelters [49]. The higher detection rates in Asian and Eastern European studies compared to Western European surveys likely reflect differences in sampling strategies (shelter vs. household cats), diagnostic methods (RT-PCR vs. virus isolation), and the inclusion of clinically affected animals versus random sampling of apparently healthy populations.

Risk factors significantly associated with FCV infection include young age, multi-cat household environments, high-density housing (shelters, catteries), lack of vaccination, and the presence of oral symptoms such as gingivostomatitis [2, 9, 33, 40]. Bayesian network modeling of Swiss FCV data confirmed that reducing group size and implementing vaccination programs are the two most impactful actionable factors for controlling FCV infection [40]. Interestingly, while vaccination is strongly protective against severe disease, it does not prevent infection or shedding, and vaccinated cats can remain persistently infected and serve as sources of viral transmission [22, 34]. The virus is shed primarily in oropharyngeal secretions, saliva, and nasal discharges, as well as in feces and urine, facilitating direct transmission through close contact, as well as indirect transmission via contaminated fomites, food bowls, bedding, and even human hands [3, 22, 45]. Environmental contamination with FCV RNA can persist for at least 28 days after cessation of shedding in the absence of disinfection, underscoring the importance of rigorous hygiene protocols in multi-cat environments [45].

FCV has a narrow host range, naturally infecting only members of the family Felidae, including domestic cats, exotic felids such as lions, tigers, and cheetahs, and possibly some members of the Canidae and Mustelidae under experimental conditions [3, 35]. There is no evidence of zoonotic transmission, and FCV does not pose a risk to human health, although it is widely used as a surrogate for human norovirus in disinfection and antiviral studies due to its similar physicochemical properties and cultivability [10, 12, 13, 19]. The virus's ability to establish persistent infections in clinically healthy carrier cats, which may shed virus intermittently for months or years, is a key epidemiological feature that sustains viral circulation within populations and confounds control efforts [3, 22].

Pathotypes and Clinical Spectrum

FCV infection is associated with a remarkable spectrum of clinical presentations, which have been categorized into several pathotypes: classical upper respiratory tract disease (URTD), chronic gingivostomatitis (FCGS), limping syndrome (transient polyarthritis), enteric disease, paw and mouth disease, and the most severe manifestation, virulent systemic disease (VSD) [3, 4, 7, 11, 15, 25, 29]. Classical URTD is the most common presentation, characterized by fever, nasal discharge, conjunctivitis, sneezing, and oral ulcerations, typically resolving within 7–14 days in otherwise healthy adults [3, 22]. FCGS is a chronic, debilitating inflammatory condition of the oral mucosa, particularly the caudal fauces and glossopalatine arches, that is strongly associated with FCV infection, with viral RNA detected in 60–100% of affected cats [9, 17, 31, 48]. Fried et al. used unbiased metatranscriptomic sequencing to demonstrate that FCV was the only microbe significantly associated with FCGS, detected in 21 of 23 affected cats and none of the controls, providing compelling evidence for a direct viral etiology [31].

The limping syndrome, or transient polyarthritis, is a distinct pathotype characterized by acute lameness, joint swelling, pyrexia, and pain, which can occur either naturally or as a post-vaccinal complication [15, 29]. Balboni et al. described three natural cases of polyarthritis in household cats, demonstrating FCV RNA and antigen in synovial membranes and synoviocytes, and providing histopathological evidence of diffuse fibrinous synovitis that persisted for up to eight months, suggesting that FCV can establish persistent infection within joints [29]. Enteric FCV strains have been increasingly recognized, and Martino et al. detected FCV RNA in 25.9% of fecal samples from diarrheic cats, with enteric isolates demonstrating greater resistance to low pH, trypsin, and bile salts compared to respiratory isolates, supporting the hypothesis that some FCV lineages may acquire enteric tropism [38]. Paw and mouth disease, a rare but distinct presentation, involves cutaneous ulceration and edema of the paws, often accompanied

Molecular Pathogenesis of Feline Calicivirus

The molecular pathogenesis of Feline Calicivirus (FCV) is a multifaceted and dynamic interplay between a highly plastic RNA virus and its feline host, characterized by sophisticated strategies for cellular entry, genome release, replication complex assembly, host protein synthesis shutoff, innate immune evasion, and the induction of programmed cell death. Understanding these intricate molecular mechanisms is paramount for deciphering the wide spectrum of clinical outcomes, from subclinical infections and mild upper respiratory tract disease (URTD) to the devastating and often fatal virulent systemic disease (VS-FCV), and for informing the development of novel therapeutic interventions and efficacious vaccine strategies. The virus's classification within the Caliciviridae family, genus Vesivirus, is defined by a single-stranded, positive-sense RNA genome of approximately 7.7 kb, organized into three major open reading frames (ORFs): ORF1 encodes a large polyprotein processed into non-structural proteins (including p30, p32, p39, the protease-polymerase PP, and VPg), ORF2 encodes the major capsid protein VP1 (expressed initially as a precursor, LC-VP1), and ORF3 encodes the minor capsid protein VP2 [4, 47]. The molecular pathogenesis is a direct consequence of the coordinated functions of these viral proteins.

Attachment, Entry, and Genome Release: The Portal and the Pore

The initial step in FCV pathogenesis is the specific attachment of the viral capsid to the feline junctional adhesion molecule-A (fJAM-A) on the surface of susceptible host cells. The hypervariable E region of the VP1 capsid protein, particularly the P2 subdomain, is the primary determinant for receptor binding and a major target for neutralizing antibodies [2, 8, 39, 42]. Following receptor engagement, the virus is internalized via clathrin-mediated endocytosis. The critical event of genome release into the cytoplasm, a process long considered a black box in calicivirus biology, has been recently elucidated. It is now understood that the acidic environment of the early endosome triggers a dramatic conformational change in the capsid. This process is mediated by the minor capsid protein VP2, which, upon receptor engagement and low pH, forms a portal-like assembly at a unique five-fold axis of the icosahedral capsid, providing a channel for the RNA genome to exit [6]. Sun et al. (2024) demonstrated that VP2, rich in hydrophobic N-terminal residues, functions as a bona fide pore-forming protein, puncturing the endosomal membrane to release the viral genomic RNA (gRNA) into the cytoplasm [6]. This elegant mechanism highlights VP2 not merely as a structural component but as a dynamic effector of membrane penetration, a process that is accelerated in the early endosomes [6]. Concurrently, the leader of the capsid (LC) protein, a unique feature of vesiviruses cleaved from the VP1 precursor, acts as a viroporin. While lacking a classic transmembrane domain, LC oligomerizes via disulfide bonds and induces membrane permeability, contributing to the disruption of cellular membranes and facilitating viral replication [27]. The LC protein's viroporin activity is also coupled with its pro-apoptotic functions, linking early entry events to late-stage pathogenesis [27, 44].

Replication Complex Assembly and Hijacking of Host Machinery

Once released, the positive-sense gRNA is translated to produce the viral non-structural proteins, which orchestrate the formation of membrane-associated replication complexes (RCs). The viral protease-polymerase (PP) is central to this process [37]. FCV infection induces a massive rearrangement of intracellular membranes, primarily derived from the endoplasmic reticulum and Golgi apparatus, creating a protective environment for viral RNA replication. The host protein Annexin A2 (AnxA2), a lipid-raft associated scaffold protein, is recruited to these RCs. AnxA2 binds directly to the FCV gRNA and colocalizes with the viral NS6/7 protein (within PP) and double-stranded RNA (dsRNA) replication intermediates. Knockdown of AnxA2 significantly impairs viral protein synthesis, dsRNA production, and overall virus yield, demonstrating its essential role as a proviral host factor for efficient FCV replication [51]. The replicase complex, including the RNA-dependent RNA polymerase (RdRp) within PP, is responsible for the error-prone replication characteristic of FCV, generating the high genetic diversity that underpins its antigenic variability and pathotypic plasticity [3, 4].

Host Shutoff and Translational Control

A hallmark of FCV pathogenesis is its ability to globally suppress host gene expression, a process known as host shutoff, which dismantles antiviral responses and redirects cellular resources to viral replication. The viral PP protein has been identified as a potent shutoff factor. Wu et al. (2021) demonstrated that FCV infection promotes the degradation of both endogenous and exogenous mRNAs, leading to a global inhibition of host protein synthesis [37]. The PP protein, independent of other viral or cellular factors, possesses intrinsic RNase activity in vitro. It preferentially targets RNA polymerase II-transcribed mRNAs in a ribosome-, 5′ cap-, and 3′ poly(A) tail-independent manner, and this degradation process is completed by the host 5′-3′ exoribonuclease Xrn1 [37]. This represents a newly discovered strategy for FCV to evade the host immune response. Furthermore, the virus employs a unique translational strategy for its own major capsid protein. Although VP1 is primarily translated from a subgenomic RNA, Urban and Luttermann (2020) showed that a precursor form of VP1 is also expressed from the genomic RNA via a translation initiation event within the LC coding region, producing a truncated LC-VP1 (tLC-VP1) protein that is critical for efficient viral replication [46]. This suggests that VP1 may play an early, non-structural role in the replication cycle before its function in virion assembly [46].

Modulation of Innate Immunity: Evasion and Subversion

FCV has evolved multiple sophisticated mechanisms to antagonize the host's innate immune defenses, particularly the type I interferon (IFN) system. The non-structural protein p30 is a key antagonist. Tian et al. (2020) discovered that the p30 protein from the virulent FCV strain 2280 directly and selectively degrades IFNAR1 mRNA, which encodes a subunit of the type I interferon receptor. This degradation blocks the JAK-STAT signaling pathway, preventing the transcription of interferon-stimulated genes (ISGs) and rendering the virus resistant to the antiviral effects of IFN-β [41]. Remarkably, this activity is strain-specific, as the p30 from the attenuated vaccine strain F9 lacks this nuclease activity, directly linking this immune evasion function to viral virulence [41]. Another layer of innate immune suppression involves the manipulation of autophagy. FCV infection triggers autophagy, and the non-structural proteins P30, P32, and P39 are responsible for its induction. Mao et al. (2023) demonstrated that this induced autophagy is co-opted by the virus to degrade the innate immune sensor retinoic acid-inducible gene I (RIG-I), thereby dampening the RIG-I-mediated signaling cascade and reducing IFN production [16]. This autophagic degradation of RIG-I represents a novel immune evasion tactic that promotes viral replication. The host responds with factors like interferon regulatory factor 1 (IRF1), which acts as a potent antiviral factor by inducing IFN-β and other ISGs; however, FCV infection actively reduces IRF1 levels, further tilting the balance in favor of the virus [52].

Induction of Apoptosis and the Role of the LC Protein

FCV infection ultimately leads to the induction of apoptosis, a process that is crucial for viral dissemination and the pathogenesis of tissue damage, particularly in the oral mucosa and, in cases of VS-FCV, in multiple organ systems. The leader of the capsid (LC) protein is the primary viral effector of apoptosis. LC expression alone is sufficient to downregulate the anti-apoptotic proteins survivin and XIAP, leading to the translocation of Smac/DIABLO from the mitochondria to the cytoplasm, activation of caspase-3, and subsequent execution of the intrinsic apoptotic pathway [44]. The LC protein’s viroporin activity and its role in apoptosis are functionally linked; the C40A mutant of LC, which is defective in oligomerization and viroporin function, fails to induce apoptosis, suggesting that membrane permeabilization is a prerequisite for the initiation of the death cascade [27, 44]. The timely induction of apoptosis facilitates the release of progeny virions while potentially limiting a robust inflammatory response that would otherwise clear the infection.

Molecular Basis of Pathotype Heterogeneity: From Classical to Virulent Systemic Disease

The molecular mechanisms underlying the dramatic shift in virulence from classical, self-limiting URTD to the highly fatal VS-FCV remain a central question in FCV pathogenesis. VS-FCV strains exhibit a broader tissue tropism, causing systemic vascular compromise, severe cutaneous edema, and multi-organ failure [7, 11]. Despite extensive sequencing, no single genetic marker has been identified that consistently distinguishes VS-FCV from classical FCV strains [21, 47, 50]. However, sophisticated analyses have revealed pathotype-associated signatures. Brunet et al. (2019) applied a multiple correspondence analysis to amino acid properties within the hypervariable E region of VP1 and successfully differentiated VS-FCV and classical strains based on seven specific residue positions, primarily in the N-terminal hypervariable subregion, which may influence post-binding conformational changes and interactions with fJAM-A and VP2 [42]. This suggests that the difference in virulence may not be a single linear epitope but a complex set of structural and biochemical properties influencing entry and uncoating dynamics. Recombination, particularly intergenic recombination between ORF1 and ORF2, is a powerful evolutionary force driving the emergence of new strains, including those associated with hemorrhagic-like disease and VS-FCV [2, 20, 24, 36]. The emergence of VS-FCV is a stark reminder of the virus's evolutionary plasticity, where a constellation of mutations in the capsid and non-structural proteins, including p30, PP, and LC, can collectively shift the virus from a mucosal pathogen to a systemic killer [41, 47]. The molecular pathogenesis of FCV is therefore a continuous arms race, where the virus's capacity for error-prone replication and recombination constantly generates new variants with altered pathogenic potential, challenging our ability to control this ubiquitous feline pathogen.

Epidemiology and Risk Factors of Feline Calicivirus Infection

Feline calicivirus (FCV) represents one of the most globally pervasive viral pathogens affecting domestic cats, with a prevalence that underscores its significance in feline medicine and public health surveillance as a surrogate for human noroviruses [3, 4, 22]. The virus exhibits a remarkable capacity for sustained circulation within feline populations, driven by its high mutation rate, genetic plasticity, and ability to establish persistent infections in apparently healthy carriers [3, 4, 22]. The World Organisation for Animal Health (WOAH) recognizes FCV as a critical component of feline respiratory disease complex, and the virus is frequently included in global surveillance frameworks for emerging calicivirus threats. Understanding the intricate epidemiological landscape of FCV is paramount for designing effective control strategies, optimizing vaccination protocols, and anticipating the emergence of highly virulent strains that pose substantial risks to both individual animals and multi-cat populations.

Global Prevalence and Geographic Distribution

The prevalence of FCV infection varies considerably across geographic regions, study populations, and diagnostic methodologies employed. Comprehensive cross-sectional studies have consistently demonstrated that FCV is ubiquitous in domestic cat populations worldwide. A large-scale, multi-national European study encompassing six countries (UK, Sweden, Netherlands, Germany, France, and Italy) and utilizing randomly selected veterinary practices reported an overall FCV prevalence of 9.2% among clinically presented cats [49]. This figure, however, is likely an underestimate of the true population-level prevalence, as the study sampled cats attending veterinary practices for various reasons, not exclusively those with respiratory signs. In stark contrast, studies focusing on cats with upper respiratory tract disease (URTD) or those from high-density environments report substantially higher detection rates. In Switzerland, a study examining cats suspected of FCV infection found that less than half tested positive, yet oral ulcerations and gingivitis-stomatitis were more commonly associated with FCV detection than classical upper respiratory signs [22].

Contemporary data from China reveal some of the highest prevalence rates documented globally. In Beijing, a 2023 study of 402 cats from the China Agricultural University Veterinary Teaching Hospital (CAUVTH) reported an FCV-positive rate of 31.3% using RT-PCR [2]. Similarly, in Kunshan, molecular screening of nasopharyngeal swabs from cats with variable clinical signs between 2022 and 2023 identified FCV RNA in 52 of 200 samples (26%) [5]. A longitudinal investigation in Hangzhou encompassing 516 cats from 2018 to 2020 found an even higher prevalence of 43.0% [33]. In Guangdong Province, analysis of 152 nasal and throat swabs collected from 2018 to 2022 yielded a detection rate of 28.9% [23], while in Nanjing, 36 of 86 nasopharyngeal swabs (41.86%) from cats with respiratory symptoms tested positive in 2020 [28]. A broader survey across multiple regions of China involving 337 cat swab samples collected between 2019 and 2021 reported a positive rate of 29.9% [32]. These figures collectively indicate that FCV is hyperendemic in Chinese cat populations, with prevalence rates frequently exceeding 25% and approaching 50% in symptomatic cohorts.

Outside of Asia, prevalence patterns show considerable variation. In the Moscow metropolitan area, a large-scale surveillance effort examining 6,213 animals from 2018 to 2021 detected the FCV genome in 1,596 samples (25.7%), with annual positivity rates fluctuating from 18.9% in 2018 to 32.6% in 2021, suggesting cyclical epidemiological patterns and sustained circulation [30]. In Thailand, a study spanning 2016 to 2021 detected FCV in 46.7% of 184 cats using RT-qPCR, representing one of the highest prevalence rates reported in a single study and highlighting the substantial burden of this pathogen in Southeast Asia [9]. In Iraq, a molecular investigation of 200 cats in Mosul city confirmed FCV circulation at significant levels, with the highest infection rates observed in oropharyngeal swabs compared to conjunctival samples [60]. Conversely, a study of healthy stray cats in Korea reported a markedly lower prevalence of only 2.5% (3/120) based on virus isolation and a novel RT-PCR assay, suggesting that healthy, free-roaming populations may harbor the virus at lower rates than clinically ill or shelter-housed cats [63]. The prevalence data from Brazil, where 26 conjunctival samples from cats in shelters and multicat households were analyzed, revealed that FCV variants belong predominantly to genogroup I, with high variability observed in short-term shelter environments due to rapid turnover of carrier cats [65]. These geographic disparities underscore the critical role of population density, management practices, and diagnostic sensitivity in shaping observed prevalence estimates.

Co-infection Patterns and Diagnostic Implications

FCV rarely circulates in isolation, particularly in cats presenting with clinical signs of feline upper respiratory tract disease (URTD). The virus is frequently detected alongside other major feline pathogens, most notably feline herpesvirus 1 (FHV-1), feline panleukopenia virus (FPV), and feline infectious peritonitis virus (FIPV). A recent quadruplex TaqMan MGB fluorescent quantitative PCR study analyzing 381 fecal samples from cats detected FCV in 26.77% (102/381), FHV-1 in 18.37%, FPV in 13.65%, and FIPV in 9.71%, with a notable trend of increasing mixed infections [1]. In Thailand, co-infection with FCV and FHV-1 was detected in 31.5% of sampled cats, and the odds ratio analysis revealed a strong association between single FCV detection and the presence of gingivostomatitis lesions (OR: 7.15, 95% CI: 1.89–26.99, p = 0.004) [9]. Another study utilizing a dual enzymatic recombinase amplification (ERA) method on 50 nasopharyngeal swabs from cats with respiratory symptoms found FCV and FHV-1 positive rates of 40% and 14%, respectively, with a co-infection rate of 10% [56]. Triple NanoPCR methods have demonstrated that among clinical samples, the positive rates for FCV, FPV, and FHV-1 can reach 63.16%, 31.58%, and 60.53%, respectively, substantially higher than those detected by conventional PCR [58]. These findings highlight that reliance on single-pathogen diagnostic approaches severely underestimates the true burden of FCV and its role in polymicrobial disease, and underscore the necessity for multiplex molecular assays for accurate clinical diagnosis and epidemiological surveillance [1, 53, 56-58]. The high sensitivity and specificity of modern diagnostic platforms, including CRISPR-Cas13a-based assays capable of detecting as few as 5.5 copies/μL, have revolutionized our ability to identify FCV in clinical specimens and track its molecular epidemiology with unprecedented precision [53, 59].

Risk Factors for FCV Infection and Shedding

Age as a Predominant Risk Factor

Age consistently emerges as one of the most significant risk factors associated with FCV infection across multiple epidemiological studies. Young cats, particularly those under one year of age, exhibit substantially higher rates of FCV detection compared to adult animals. In Beijing, statistical analysis demonstrated a significant association between FCV infection and younger age [2]. Similarly, in Kunshan, a strong correlation was identified between FCV positivity and age, with kittens and juvenile cats being disproportionately affected [5]. In Hangzhou, age was identified as a significant risk factor, with cats older than two years showing higher odds of having pre-vaccination neutralizing antibodies (OR: 7.091; p = 0.022), reflecting cumulative exposure over time [33, 64]. The multi-national European study found that younger age was positively associated with FCV shedding, likely due to the waning of maternally derived antibodies and the increased susceptibility of kittens encountering virus for the first time in high-density environments [49]. In the Moscow metropolitan area, the age distribution of FCV-positive cats mirrored global patterns, with younger animals disproportionately represented among positive cases [30]. Conversely, a study in Iraq reported the highest infection rates in cats older than six months, with infection rates decreasing with advancing age, a pattern that may reflect age-related changes in immune competence or exposure risk rather than a protection effect [60]. The biological basis for age susceptibility is multifactorial: kittens have immature immune systems, are more likely to be housed in crowded conditions such as shelters or breeding catteries, and have not yet developed the adaptive immune responses that accompany natural infection or vaccination. The high turnover of susceptible juveniles in these environments sustains viral circulation and contributes to the endemic nature of FCV [32].

Vaccination Status and Vaccine Efficacy

Vaccination status represents a critical modifying factor in FCV epidemiology, yet its protective effect is complex and often incomplete. Multiple studies have demonstrated that vaccinated cats are significantly less likely to test positive for FCV compared to unvaccinated counterparts. In Thailand, FCV detection was notably less likely in vaccinated cats (OR: 0.22, 95% CI: 0.07–0.75, p = 0.015) [9]. In Beijing, vaccination status was identified as a significant risk factor, with vaccinated cats showing reduced odds of infection [2]. Similarly, in Hangzhou, vaccinated cats had a significantly different distribution of serum antibody titers compared to unvaccinated cats, and lack of vaccination was strongly associated with FCV positivity [33]. In Mosul, Iraq, non-vaccinated cats recorded the highest infection rates with FCV [60]. The multi-national European study further corroborated these findings, demonstrating that cats with a history of vaccination were less likely to shed FCV [49].

However, the protective efficacy of vaccination is far from absolute. Despite widespread vaccination, FCV continues to circulate at high levels in vaccinated populations [5, 7, 9, 18, 26, 34]. The virus’s high mutation rate and genetic diversity, particularly within the hypervariable E region of the major capsid protein VP1, contribute to antigenic drift that can render vaccine-induced antibodies less effective against circulating field strains [2, 5, 26, 54, 55]. In Kunshan, researchers identified that despite regular vaccination practices, new FCV cases still occur, and amino acid variations in the capsid protein potentially affect vaccination efficacy and FCV detection [5]. In southwestern China, cross-neutralization assays demonstrated that sera from mice immunized with three different FCV isolates and a commercial vaccine showed neutralizing antibody titers ranging from 1:19 to 1:775, whereas the triple-inactivated vaccine induced titers of only 1:16, indicating that different genogroup/sub-genogroup strains exhibit significantly variable cross-reactivity [26]. A study comparing the FCV-F9 vaccine strain against field isolates from 2001 and 2013/2014 found that despite extensive genetic diversity, FCV-F9 antisera remained broadly and equally cross-reactive to both temporally separated populations, suggesting that the immunodominant neutralization region may be structurally constrained [43]. Nonetheless, inactivated bivalent vaccines containing screened epidemic strains (FCV-HB7 and FCV-HB10) have demonstrated superior cross-neutralizing antibody titers against multiple representative FCV strains compared to the commercial FCV-255 vaccine, highlighting the potential for improved vaccine formulations [18]. The modified-live FCV vaccination has been shown to significantly reduce clinical scores, viral RNA loads from the oropharynx, and the duration of RNAemia after heterologous challenge, even in the absence of complete sterilizing immunity [34, 62]. Importantly, vaccination induces cellular immunity, including Th1 cytokine responses and IFN-γ-releasing peripheral blood mononuclear cells, which contribute to protection against disease even when neutralizing antibodies are strain-specific [62].

Living Environment and Population Density

The living environment and residential density are among the most influential risk factors driving FCV transmission dynamics. High-density housing, such as shelters, breeding catteries, and multicat households, dramatically increases the probability of FCV infection [2, 5, 32, 49]. In Beijing, residential density was identified as a significant risk factor, with cats from multi-cat environments showing higher infection rates [2]. The Kunshan study similarly found a significant association between living environment and FCV positivity [5]. A comprehensive study across multiple regions of China demonstrated that living environment was significantly associated with FCV prevalence (p = 0.0004) [32]. The multi-national European study confirmed that multi-cat households were positively associated with FCV shedding [49]. In Thailand, the detection rates for FCV were substantially higher in shelter and multicat household settings compared to single-cat households [9].

The mechanisms underlying this association are well-established. FCV is highly contagious and is transmitted primarily through direct contact with infected saliva, ocular secretions, and nasal discharges, as well as indirectly through contaminated fomites, including food bowls, bedding, grooming equipment, and human hands [3, 4, 45]. In high-density environments, the frequency and intensity of contact between cats are amplified, facilitating rapid virus spread. Furthermore, the virus can persist in the environment for extended periods; a study on environmental contamination demonstrated that FCV viral RNA remained detectable on various items and surfaces, including cat hair, for at least 28 days after shedding had ceased [45]. The high turnover of cats in shelters, with constant introduction of new animals carrying diverse FCV strains, maintains a dynamic and evolving viral population [65]. Bayesian network modeling applied to FCV data from Switzerland identified that reducing group size was one of the two actionable factors directly associated with FCV status, alongside vaccination, and was a primary target for controlling FCV infection [40]. The outdoor lifestyle has also been identified as a risk factor for vaccine response, with outdoor cats more likely to have a ≥4-fold ELISA titer increase after vaccination, likely due to more frequent natural exposure boosting immune responses [64].

Breed and Sex as Contributing Factors

The influence of breed and sex on FCV susceptibility remains controversial, with most studies reporting non-significant associations. In Kunshan, a significant association was found between FCV-positive detection rate and gender, with males potentially at higher risk [5]. However, in a large Chinese multicenter study, sex was not significantly associated with FCV prevalence (p = 0.092) [32]. Similarly, breed was not significantly associated with FCV infection in the same study (p = 0.171) [32]. The Kunshan study also found a non-significant association with breed [5]. The multi-national European study did not identify breed as a significant risk factor [49]. Nonetheless, some evidence suggests that genetic background of cats might influence their susceptibility to FCV infection, as noted in Swiss studies [22]. Anecdotal reports and case studies have documented FCV infection in specific breeds, such as a Bengal cat with chronic stomatitis, rhinitis, and otitis in Indonesia, but these do not establish breed predisposition [61]. The lack of consistent breed or sex effects across studies suggests that environmental and management factors, rather than intrinsic host genetic factors, are the primary drivers of FCV epidemiology. However, there may be subtle genetic influences that modulate immune responses to FCV infection or vaccination, which warrant further investigation using genome-wide association studies [22].

Clinical Status and Oral Disease Associations

FCV is strongly associated with specific clinical presentations, particularly oral cavity diseases. Chronic gingivostomatitis (FCGS) has been consistently linked to FCV infection. In Thailand, the odds ratio analysis revealed a strong association between detection of FCV alone and the presence of gingivostomatitis lesions (OR: 7.15, 95% CI: 1.89–26.99, p = 0.004) [9]. In Switzerland, Bayesian network modeling showed that the presence of gingivostomatitis and Mycoplasma felis was directly associated with FCV status, whereas signs of upper respiratory tract disease were not [40]. This finding is particularly significant as it suggests that FCV’s pathogenic role extends beyond classical respiratory disease, with chronic oral inflammation being a hallmark of infection. In cats with FCGS, FCV antigens were identified in 60% of oral mucosal biopsies, and natural killer (NK) cells were present in all samples, though no statistical association was found between FCV infection and NK cell numbers [17]. Metatranscriptomic analysis of caudal oral mucosal swabs from FCGS-affected cats identified FCV as the only microbe strongly associated with the disease, detected in 21 of 23 affected cats but in none of the control cats [31]. Furthermore, a retrospective study of 104 cats with FCGS found that presence of lingual ulcers was significantly correlated with FCV load (p = 0.0325), although the overall oral FCV load was not correlated with severity of lesions or treatment outcome after dental extractions [48].

Limping syndrome and polyarthritis are less common but well-recognized manifestations of FCV infection. A small outbreak of FCV-associated limping disease in household cats demonstrated that the virus can affect joints, resulting in lameness, and that transmission likely occurred indirectly via virus shed into the environment from the respiratory tract [15]. Retrospective analysis of three clinical cases of lameness in household cats naturally infected with FCV confirmed polyarthritis, with FCV RNA or antigens detected in symptomatic joints. Histopathology in one euthanized cat revealed diffuse fibrinous synovitis and osteoarthritis persisting eight months after lameness onset and first detection of FCV RNA, supporting the hypothesis of persistent infection in synovial tissues [29]. These findings underscore the diverse clinical spectrum of FCV infection and the importance of considering FCV in differential diagnoses for lameness of unknown origin.

Virulent Systemic FCV: A Distinct Epidemiological Entity

The emergence of virulent systemic feline calicivirus (VS-FCV) represents a paradigm shift in our understanding of FCV pathogenesis and epidemiology. VS-FCV strains cause a highly fatal systemic disease distinct from classic oronasal FCV infection, characterized by severe cutaneous ulcerations, limb edema, icterus, hemorrhagic diathesis, and high mortality rates, even in adequately vaccinated cats [7, 11, 21, 47, 50]. Outbreaks of VS-FCV have been documented globally, including in the United States, United Kingdom, continental Europe, Australia, and Asia [7, 11, 21]. A nosocomial outbreak in Korea involving 18 cats over a six-month period resulted in an overall mortality rate of 72.2%, with anorexia, lethargy, fever, and limb edema being the most common clinical signs, and lymphopenia and macrothrombocytopenia as the most frequent hematological findings [7]. In Australia, three outbreaks of FCV-VSD among 23 cases yielded a 39% mortality rate, with metagenomic sequencing identifying five genetically distinct FCV lineages evolving in situ [21]. The first known case of VS-FCV infection in Ireland was reported in an 11-month-old vaccinated domestic shorthair cat presenting with lethargy, decreased appetite, and progressively worsening pitting

Clinical Spectrum and Disease Manifestations

Feline calicivirus (FCV) is a highly mutable, single-stranded RNA virus belonging to the family Caliciviridae that exhibits a remarkably broad and heterogeneous clinical spectrum, ranging from subclinical infections to rapidly fatal systemic disease [3, 4]. This diversity in clinical presentation is a direct consequence of the virus's high genetic plasticity, its capacity for antigenic drift, and the emergence of distinct pathotypes that differ fundamentally in their tissue tropism and pathogenic mechanisms [4, 22]. The clinical manifestations of FCV infection can be broadly categorized into several overlapping syndromes, including classical upper respiratory tract disease (URTD), oral disease, limping syndrome, enteric disease, and the most severe form, virulent systemic disease (VS-FCV). Understanding this spectrum is critical for accurate diagnosis, effective management, and the implementation of appropriate biosecurity measures, particularly in multi-cat environments where the virus is endemic.

Classical Upper Respiratory Tract Disease and Oral Manifestations

The most commonly recognized presentation of FCV infection is acute URTD, often referred to as "cat flu." This syndrome is characterized by a constellation of signs including pyrexia, serous to mucopurulent nasal discharge, conjunctivitis, sneezing, and depression [1, 3, 4]. However, a landmark study from Switzerland demonstrated that oral ulcerations, salivation, and gingivitis-stomatitis are more consistently associated with FCV infection than are classic respiratory signs, with less than half of the cats suspected of having FCV infection actually testing positive for the virus [22]. This observation underscores the primacy of oral pathology in the clinical diagnosis of FCV. The characteristic oral lesions are typically vesicular or ulcerative, most commonly found on the tongue (particularly the dorsum and margins), the hard palate, the gingiva, and the lips [22, 48]. These ulcers are often painful, leading to ptyalism, anorexia, and reluctance to eat. The pathogenesis of these lesions involves direct viral cytopathology in the epithelial cells of the oral mucosa, followed by a robust local inflammatory response.

The prevalence of FCV in cats presenting with URTD is substantial. A large-scale European cross-sectional study involving six countries found an overall FCV prevalence of 9.2%, with risk factors including multi-cat households, chronic gingivostomatitis, and younger age [49]. In China, detection rates in clinically affected cats range from 23.5% to 43.0%, with significant associations observed with age, vaccination status, and living environment [2, 5, 33]. For instance, a study in Beijing reported a 31.3% positivity rate, with unvaccinated cats and those from high-density housing being at significantly higher risk [2]. Similarly, investigations in Kunshan and Nanjing found FCV in 26% and 41.9% of sampled cats, respectively, confirming the virus's endemic nature in these populations [5, 28]. Co-infections are exceedingly common, particularly with feline herpesvirus-1 (FHV-1), feline panleukopenia virus (FPV), and feline infectious peritonitis virus (FIPV), which can complicate the clinical picture and exacerbate disease severity [1, 9, 53, 56-58, 66]. A quadruplex PCR study of 381 fecal samples detected FCV in 26.8% of cases, with co-infections with FHV-1 and FPV being frequently observed [1]. In Thailand, a staggering 46.7% of cats were FCV-positive, with a 31.5% co-infection rate with FHV-1 [9].

Feline Chronic Gingivostomatitis (FCGS)

A particularly debilitating and frustrating manifestation of FCV infection is feline chronic gingivostomatitis (FCGS), a severe, immune-mediated inflammatory condition of the oral cavity. FCGS is characterized by intense, proliferative, and ulcerative inflammation of the gingiva and the caudal oral mucosa (caudal stomatitis), often extending to the palatoglossal folds and the fauces [17, 31, 48]. The etiopathogenesis of FCGS is complex and multifactorial, but FCV is strongly implicated as a key initiating or perpetuating agent. Unbiased metatranscriptomic analysis of oral mucosal swabs from FCGS-affected cats revealed that FCV was the only microbe strongly associated with the disease, detected in 21 of 23 affected cats compared to none of the control cats [31]. This finding provides compelling evidence for a direct viral component in FCGS pathogenesis. Immunohistochemical studies have identified FCV antigens within the lesional tissue, alongside a prominent infiltration of natural killer (NK) cells, suggesting an ongoing antiviral immune response that becomes dysregulated and chronic [17]. The severity of oral lesions, particularly the presence of lingual ulcers, has been positively correlated with FCV viral load in oropharyngeal swabs [48]. However, the relationship between viral load and treatment outcome following dental extractions is less clear, with one study finding no significant correlation between pre-operative FCV load and the likelihood of clinical cure [48]. This suggests that while FCV may trigger the disease, the chronic inflammatory process becomes self-perpetuating and independent of ongoing viral replication in many cases.

Limping Syndrome and Polyarthritis

A distinct and intriguing clinical manifestation of FCV infection is the "limping syndrome," an acute, transient lameness that can occur either naturally or following vaccination with modified-live FCV vaccines [15, 29]. This syndrome is characterized by a shifting lameness, pyrexia, and pain on manipulation of the joints, typically resolving spontaneously within 48 to 72 hours. The pathogenesis involves direct viral infection of the synovial membranes, leading to an acute, non-suppurative polyarthritis. This has been confirmed by the detection of FCV RNA and antigens within the synovium and synovial fluid of affected joints [29]. In a retrospective study of three naturally infected cats with polyarthritis, FCV was demonstrated by immunohistochemistry in synoviocytes and fibroblasts of the synovial membranes, and in one case, the infection persisted for at least eight months, leading to chronic fibrinous synovitis and osteoarthritis [29]. This finding challenges the notion that limping syndrome is always a self-limiting condition and suggests that persistent FCV infection of the joints can occur, leading to chronic joint pathology. A small outbreak of limping disease in two household cats was meticulously documented, with the complete genome sequence of the virus revealing 39 synonymous nucleotide mutations between the isolates, indicating that the virus retained the limping pathotype during transmission [15]. This demonstrates that the ability to cause lameness is a stable property of certain FCV strains.

Enteric Disease

While FCV is traditionally considered a respiratory pathogen, its role as an enteric pathogen is increasingly recognized. FCV RNA has been detected in the feces of cats with diarrhea, and enteric isolates have been successfully cultured [24, 38]. A pivotal study identified FCV RNA in 25.9% of stool samples from cats with enteritis, compared to 0% of healthy controls, strongly suggesting a causal role [38]. Importantly, the enteric isolates were found to be genetically heterogeneous and phenotypically distinct from respiratory isolates, exhibiting greater resistance to low pH, trypsin, and bile salts [38]. This phenotypic adaptation is consistent with a virus that must survive the harsh conditions of the gastrointestinal tract to establish infection. The complete genome sequence of one enteric strain, 160/2015/ITA, was determined, and phylogenetic analysis revealed that it clustered separately from typical respiratory strains [38]. Furthermore, a study from Guangxi, China, isolated FCV strains from both respiratory and enteric sources, with the enteric viruses being genetically heterogeneous and showing evidence of recombination with respiratory strains [24]. These findings indicate that FCV can acquire an enteric tropism and that the enteric tract may serve as an important reservoir for viral evolution and recombination, potentially contributing to the emergence of novel strains.

Virulent Systemic Disease (VS-FCV)

The most severe and alarming manifestation of FCV infection is virulent systemic disease (VS-FCV), a highly fatal, epizootic condition characterized by widespread systemic vascular compromise and multi-organ failure [3, 7, 11, 21, 47, 50]. VS-FCV is distinct from classical FCV infection in its clinical presentation, pathogenesis, and high mortality rate, which can range from 39% to 86% in reported outbreaks [7, 11, 21]. The disease is caused by specific, highly virulent FCV strains that have emerged sporadically and appear to have a broader tissue tropism than classical strains [42].

The clinical hallmarks of VS-FCV include severe pyrexia (often exceeding 40°C), profound lethargy, anorexia, and characteristic cutaneous lesions, which include severe ulcerative dermatitis, subcutaneous edema (particularly of the limbs and face), and icterus [7, 11, 50]. Limb edema is a particularly striking and pathognomonic sign, often described as pitting edema, and can be so severe as to impede ambulation [11]. Other common findings include lingual and cutaneous ulcers, nasal and ocular discharge, and dyspnea due to pulmonary edema or pneumonia [7, 11, 50]. Hematological abnormalities are prominent and include marked lymphopenia and macrothrombocytopenia, which are key diagnostic clues [7]. Serum biochemistry often reveals hyperbilirubinemia, elevated liver enzymes (aspartate aminotransferase), elevated creatine kinase (indicating muscle damage), and markedly increased serum amyloid A levels, reflecting a severe acute phase response [7]. The pathogenesis of VS-FCV involves a systemic vasculitis, with viral replication occurring in endothelial cells, leading to increased vascular permeability, tissue edema, and disseminated intravascular coagulation (DIC) [42, 50]. Histopathological examination of affected tissues reveals severe necrosis and inflammation in multiple organs, including the liver, spleen, lungs, and pancreas, with widespread detection of FCV antigen by immunohistochemistry [50].

The first reported outbreak of VS-FCV in Asia occurred in a referral veterinary hospital in Korea, involving 18 cats over a six-month period [7]. The overall mortality rate was a staggering 72.2%, and the hospital had to be closed and disinfected twice to contain the outbreak [7]. The first case of VS-FCV in Ireland was reported in an 11-month-old vaccinated cat that developed severe pitting edema in all four limbs, pyrexia, and lingual and cutaneous ulcers after exposure to a kitten from a high-density shelter [11]. This case highlights that even adequately vaccinated cats are not protected against VS-FCV, underscoring the antigenic distinctness of these virulent strains [11]. In Australia, three separate outbreaks of VS-FCV were investigated, with an overall mortality of 39% among 23 cases [21]. Metagenomic sequencing identified five genetically distinct FCV lineages within these outbreaks, all seemingly evolving in situ, and notably, no clear genetic markers were identified that could reliably distinguish VS-FCV from classical FCV strains [21]. This finding has been corroborated by other studies, which have failed to identify consistent amino acid changes in the major capsid protein (VP1) that differentiate the two pathotypes [21, 50]. However, a more sophisticated multiple correspondence analysis of amino acid properties within the hypervariable E region of VP1 has shown statistically significant differences between VS-FCV and classical strains, particularly at seven residue positions that may influence interactions with the cellular receptor fJAM-A or the minor capsid protein VP2 [42]. This suggests that the difference in pathogenesis may be related to subtle conformational changes affecting post-binding events during viral entry.

The emergence of VS-FCV is a global concern, with outbreaks reported in the United States, the United Kingdom, continental Europe, Australia, and Asia [7, 11, 21, 47, 50]. The virus is highly contagious and can spread rapidly within veterinary hospitals, leading to devastating nosocomial outbreaks [7]. The high mortality rate, the lack of effective antiviral therapies, and the failure of current vaccines to provide cross-protection make VS-FCV a significant threat to feline health. The World Organisation for Animal Health (WOAH) recognizes the importance of monitoring for such emerging virulent strains, as they represent a significant challenge to disease control. The mechanisms underlying the increased virulence are incompletely understood but likely involve a combination of enhanced replication efficiency, broader cellular tropism, and more effective evasion of the host innate immune response. For example, the non-structural protein p30 from a virulent FCV strain (2280) has been shown to directly degrade IFNAR1 mRNA, thereby blocking type I interferon signaling and facilitating viral replication [41]. Similarly, the proteinase-polymerase (PP) protein of FCV has been demonstrated to possess RNase activity, degrading host mRNAs to shut off host gene expression and evade the antiviral immune response [37]. These molecular mechanisms likely contribute to the enhanced pathogenicity of VS-FCV strains.

Asymptomatic Carriers and Persistent Infection

A critical aspect of FCV epidemiology is the existence of a large reservoir of asymptomatic carriers. Following acute infection, many cats fail to clear the virus and become persistently infected, shedding FCV continuously or intermittently for months to years [22, 45]. These carrier cats are often clinically healthy but serve as a constant source of infection for susceptible animals, making FCV particularly difficult to control in multi-cat environments such as shelters, catteries, and breeding colonies [22]. The prevalence of FCV shedding in healthy cats can be surprisingly high; a study of stray cats in Korea found a prevalence of 2.5% [63], while a European study reported an overall prevalence of 9.2% in cats presenting to veterinary practices [49]. The virus can persist in the environment for weeks, and viral RNA has been detected on surfaces and cat hair for at least 28 days after shedding has ceased, highlighting the importance of rigorous disinfection protocols [45]. The molecular mechanisms of persistence are not fully understood but likely involve the virus's ability to suppress the host immune response through mechanisms such as the degradation of host mRNAs by the PP protein [37] and the induction of autophagy to degrade RIG-I, a key sensor of viral RNA [16]. This ability to establish a persistent infection is a hallmark of FCV and a major driver of its endemicity.

Diagnostic Approaches for Feline Calicivirus

The accurate and timely diagnosis of feline calicivirus (FCV) infection is a cornerstone of effective clinical management, epidemiological surveillance, and infection control. This task is, however, profoundly complicated by the virus's hallmark characteristics: extreme genetic and antigenic diversity, a high mutation rate, and a broad spectrum of clinical presentations ranging from subclinical carriage to fatal virulent systemic disease (VSD). Consequently, no single diagnostic modality is universally sufficient. A comprehensive diagnostic approach must integrate clinical acumen, molecular detection, virus isolation, and increasingly, advanced point-of-care technologies, all while accounting for the specific context of the patient population and the suspected pathotype. The following section provides an exhaustive analysis of the diagnostic arsenal available for FCV, examining the strengths, limitations, and evolving landscape of each methodology.

Molecular Detection: The Gold Standard and Its Evolution

Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Its Variants

Conventional and real-time reverse transcription polymerase chain reaction (RT-PCR) have become the workhorses of FCV diagnosis, offering high sensitivity and specificity relative to traditional methods. These assays typically target conserved regions of the FCV genome, such as the ORF1 (RNA-dependent RNA polymerase) or ORF2 (major capsid protein VP1) genes. The selection of target region is critical; while the 5' end of ORF1 is highly conserved across diverse strains, the ORF2 region contains hypervariable domains, particularly the E region, which encodes immunodominant neutralizing epitopes [2, 3]. Primers targeting the ORF1 gene are thus preferable for broad detection, whereas ORF2-amplification is essential for subsequent genetic characterization and phylogenetic analysis [5, 23, 24].

A seminal advancement is the development of quantitative real-time RT-PCR (RT-qPCR), which not only confirms FCV presence but quantifies viral RNA load. This quantification holds prognostic and therapeutic relevance. For instance, in feline chronic gingivostomatitis (FCGS), while one study found no direct correlation between oral FCV load and lesion severity or treatment outcome [48], other investigations have linked higher viral loads with more severe clinical scores and systemic inflammation [34, 71]. Furthermore, RT-qPCR is indispensable for monitoring viral shedding dynamics, assessing the efficacy of antiviral therapies, and evaluating vaccine-induced reduction in viral RNAemia and shedding [34, 69, 71].

The landscape of RT-qPCR has become increasingly sophisticated through multiplexing. Given the high frequency of co-infections among feline respiratory pathogens, assays capable of simultaneously detecting FCV, feline herpesvirus-1 (FHV-1), feline panleukopenia virus (FPV), and even feline infectious peritonitis virus (FIPV) offer tremendous clinical and epidemiological utility. Wang et al. established a quadruplex TaqMan MGB RT-qPCR targeting the ORF2 of FCV, the TK gene of FHV-1, the VP2 gene of FPV, and the N gene of FIPV, achieving impressive detection limits as low as 41-53 copies/μL for each pathogen with no cross-reactivity, thereby enabling high-throughput differential diagnosis [1]. Similarly, a triplex TaqMan RT-qPCR for FCV, FHV-1, and FPV has been described, demonstrating 10- to 100-fold higher sensitivity than conventional uniplex PCR and excellent reproducibility [57].

Despite its power, conventional RT-qPCR can be confounded by the very genetic diversity it seeks to detect. False-negative results are a documented risk, particularly when primer or probe binding sites contain mismatches with emerging or recombinat strains. Metagenomic next-generation sequencing (mNGS) of FCGS lesions revealed that strains harboring problematic base-pair mismatches to common RT-PCR primers were undetectable using standard assays, yet were clearly pathogenic [31]. This underscores a critical limitation: reliance on a single set of primers, especially within the variable ORF2, may lead to systematic underdetection of certain field strains. High-resolution melting (HRM) analysis, a post-PCR technique applied in a closed-tube system, offers a solution by enabling simultaneous detection and genetic discrimination without sequencing. Phongroop et al. developed an RT-qPCR-HRM assay targeting the ORF1/ORF2 junction that could differentiate between wild-type Thai FCV strains, vaccine strains, and virulent systemic (VS-FCV) strains within a single reaction, providing a powerful tool for both diagnosis and strain typing [68].

Isothermal Amplification: Bridging the Gap to Point-of-Care

While PCR-based methods remain the gold standard, their requirement for thermal cycling equipment and relatively long turnaround times limits their application in resource-limited or field settings. Isothermal amplification techniques overcome these barriers by amplifying nucleic acid at a constant temperature, drastically reducing instrumentation needs and reaction times.

Reverse transcription loop-mediated isothermal amplification (RT-LAMP) is one such technology. A colorimetric RT-LAMP assay targeting the ORF2 gene was developed and validated, capable of visually detecting FCV within 70 minutes at 56.3°C, with a detection limit of approximately 14 copies/μL and no cross-reactivity to other feline pathogens [67]. In a comparative analysis of 54 clinical oropharyngeal swabs, both nested PCR and RT-LAMP detected FCV in 31.48% of samples, whereas conventional RT-PCR detected only 1.85% [67]. This stark difference highlights the superior sensitivity of nested and isothermal methods over legacy protocols, particularly for samples with low viral loads.

Enzymatic recombinase amplification (ERA) is another isothermal technique that has been adapted for FCV. Chen et al. developed a dual ERA method using an Exo probe for simultaneous differential detection of FCV and FHV-1. This assay achieved an impressive detection limit of 10¹ copies for both viruses, with 100% agreement to reference RT-qPCR when applied to 50 clinical nasopharyngeal swabs, demonstrating positive rates of 40% for FCV and 14% for FHV-1 [56]. The speed (typically under 20 minutes), simplicity, and high sensitivity of ERA and LAMP make them exceptionally promising for point-of-care diagnostics in veterinary clinics and shelters.

The most recent frontier in isothermal detection combines recombinase polymerase amplification (RPA) with CRISPR-Cas systems, yielding ultra-sensitive, visual, and field-deployable assays. Jiang et al. engineered a one-tube dual RPA (dRPA)-Cas12a/Cas13a assay for simultaneous detection of FHV-1 and FCV. This system leverages the collateral cleavage activity of Cas12a (targeting FHV-1 TK gene) and Cas13a (targeting FCV ORF1 gene) to generate a fluorescence signal or a lateral flow dipstick (LFD) readout. The assay achieved a remarkable limit of detection of 5.5 copies/μL for FCV, with 100% sensitivity and specificity against 56 clinical samples when using fluorometric readout [53]. A similar RPA-Cas13a-LFD assay for FCV was independently validated, detecting as few as 5.5 copies/μL and yielding a significantly higher positivity rate (67.9%) compared to RT-qPCR (44.6%) in 56 clinical specimens [59]. These CRISPR-powered platforms represent a paradigm shift, offering the sensitivity and specificity of RT-qPCR with the speed, simplicity, and visual readout of a lateral flow test.

Virus Isolation: The Historical Reference and Its Limitations

Virus isolation in cell culture, typically using Crandell-Rees feline kidney (CRFK) or F81 cells, remains a valuable, albeit slower, diagnostic approach. The characteristic cytopathic effect (CPE), rounding, detachment, and lysis of cells, is often visible within 24-72 hours post-inoculation [20, 47]. Virus isolation is not merely confirmatory; it is essential for generating live virus stocks for subsequent phenotypic characterization, such as determining the virucidal activity of disinfectants or the neutralizing capacity of antibodies [10, 12, 19, 70]. It also allows for plaque purification, which is critical for isolating clonal virus populations from mixed infections, a prerequisite for studying recombination events [20, 24].

However, isolation is constrained by several factors. It is labor-intensive, requires specialized cell culture facilities, and typically takes 3-7 days to yield definitive results. Critically, not all FCV strains replicate equally well in vitro; some field strains, particularly those with enteric tropism or those adapted to specific host environments, may grow poorly or require blind passage to produce CPE [38]. Furthermore, virus isolation from clinical samples can be confounded by the presence of cytotoxic substances, contaminating bacteria, or inadequate sample handling. Consequently, while virus isolation remains an important reference standard and a critical tool for research, it is increasingly supplanted by molecular methods for frontline clinical diagnosis.

Serological and Immunological Methods: Context and Utility

Serological detection of FCV-specific antibodies, primarily using virus neutralization (VN) tests or enzyme-linked immunosorbent assay (ELISA), provides a window into the historical exposure and immune status of a cat, rather than a diagnosis of current active infection. VN tests, which measure the titer of neutralizing antibodies against a reference strain (e.g., FCV-F9), are considered the gold standard for assessing humoral immunity. However, their interpretation is fraught with nuance. A high VN titer against the vaccine strain does not guarantee protection against a genetically and antigenically diverse field strain [43, 62]. Cross-neutralization studies consistently demonstrate that while FCV-F9 antisera can neutralize a high percentage of contemporary field isolates in vitro, the range of neutralization titers is extremely broad, and some strains require substantially higher antibody concentrations for neutralization [43, 49].

ELISAs, including blocking or competitive ELISAs, offer a more rapid and high-throughput alternative to VN for detecting FCV antibodies. They can be designed to detect antibodies against conserved epitopes, potentially providing a broader measure of seropositivity. As demonstrated by Bergmann et al., a broad-spectrum blocking ELISA identified a higher proportion of seropositive cats (77.2%) compared to VN against a single isolate (62.2%) [64]. Yet, serology is of limited value for diagnosing acute FCV infection because antibodies may not be detectable until 7-14 days post-infection, and they persist long after the resolution of clinical signs. Furthermore, maternally derived antibodies complicate serological interpretation in kittens. Thus, serology is best reserved for seroprevalence studies, vaccine response monitoring, and epidemiological investigations, rather than for diagnosing individual cases of suspected FCV infection.

Clinical Diagnosis and Pathotype Differentiation

The foundation of FCV diagnosis remains a thorough clinical examination. Classic presentations, fever, oral ulcerations (particularly on the tongue and hard palate), salivation, sneezing, nasal discharge, and conjunctivitis, are highly suggestive but not pathognomonic, as they overlap significantly with FHV-1, Chlamydia felis, and Mycoplasma spp. infections [3, 22, 40]. The presence of limping syndrome (acute, shifting lameness associated with synovitis) or, more alarmingly, the clinical hallmarks of virulent systemic disease (VS-FCV), fever, limb edema, cutaneous ulceration, jaundice, and high mortality, should immediately raise suspicion for FCV involvement [7, 11, 21, 25, 50].

Distinguishing between classical respiratory FCV and VS-FCV is a major diagnostic challenge. Genetically, no single conserved mutation in the capsid protein reliably separates the two pathotypes [21, 50]. However, a sophisticated multiple correspondence analysis (MCA) of amino acid properties within the hypervariable E region of VP1 revealed that seven specific residue positions, primarily located in the N-terminal segment of this region, could differentiate VSD from classical strains [42]. This suggests that the difference likely involves post-binding conformational changes and interactions with the fJAM-A receptor and VP2, rather than a simple linear sequence motif [6, 42]. The diagnosis of VS-FCV thus relies on a composite picture: compatible clinical and histopathological findings (e.g., vascular necrosis, multi-organ involvement), exclusion of other causes such as feline panleukopenia virus (a common co-pathogen in VSD cases) [50], and positive FCV detection by RT-PCR from blood or internal organs, a stark contrast to the localized oropharyngeal shedding seen in classical disease [7, 11]. A negative FCV RT-PCR in blood following clinical recovery further supports a diagnosis of acute systemic infection [11].

Diagnostic Considerations for Sample Type and Collection

The choice of sample type profoundly influences diagnostic yield. For classical respiratory disease and subclinical carriers, oropharyngeal or tonsillar swabs are the samples of choice, as they consistently yield the highest viral loads [60, 63]. Conjunctival swabs are less reliable. For suspected VS-FCV, whole blood or serum should be collected in addition to oropharyngeal swabs, as RNAemia is a key feature of systemic infection [7, 11]. Enteric FCV strains can also be detected in fecal samples, and their presence should not be overlooked in cats with diarrhea, as they may be genetically distinct from respiratory isolates and require specific detection protocols [24, 38]. For post-mortem diagnosis, fresh-frozen lung, spleen, and liver tissues are optimal for RT-PCR, virus isolation, and immunohistochemistry [47, 50].

Genetic Diversity and Antigenic Variation of FCV

Feline calicivirus (FCV) exemplifies the evolutionary dynamism inherent to single-stranded RNA viruses, a trait that underpins its persistent circulation, diverse clinical manifestations, and the considerable challenges it poses to diagnostic accuracy and vaccine efficacy. The genetic and antigenic plasticity of FCV is not a mere academic curiosity; it is the central biological driver of the virus's success as a pathogen, enabling it to evade host immune responses, emerge in novel pathotypes such as virulent systemic disease (VS-FCV), and maintain endemicity even in vaccinated populations. A comprehensive understanding of this diversity, from the molecular mechanisms of mutation and recombination to the population-level patterns of genotype distribution, is essential for designing rational control strategies, including next-generation vaccines and molecular diagnostics.

Molecular Mechanisms Driving Genetic Variability

The fundamental basis of FCV genetic diversity lies in the error-prone nature of its RNA-dependent RNA polymerase (RdRp), encoded within the ORF1 polyprotein. The lack of proofreading activity in the viral polymerase results in a high mutation rate, estimated to be on the order of 10⁻³ to 10⁻⁵ substitutions per nucleotide per replication cycle, a rate that is characteristic of RNA viruses and is a primary engine of genetic drift [4, 22]. This high mutational frequency allows FCV to exist as a quasispecies, a dynamic population of closely related but genetically distinct viral variants within a single host. This swarm of variants provides a reservoir of genetic diversity from which the virus can rapidly adapt to selective pressures, including host immune responses, antiviral drugs, and changes in cell tropism [4, 24].

Beyond point mutations, recombination represents a profound and potentially more dramatic mechanism for generating genetic novelty in FCV. Recombination events, particularly intergenic recombination between the ORF1 and ORF2 regions, have been documented with increasing frequency and are recognized as a significant force in FCV evolution [2, 20, 24, 26, 36]. These events can occur when a host cell is co-infected with two distinct FCV strains, allowing for template switching by the viral polymerase during RNA replication. The resulting chimeric genomes can combine advantageous traits from different parental strains, such as the replication machinery of one lineage with the antigenic capsid of another. The first recombinant FCV strain identified in Beijing, for instance, was traced to a recombination event between two earlier strains circulating in 2019 [2]. Similarly, a recombinant strain isolated in Qingdao (qd/2019/china) was shown to have originated from a recombination between a Chinese strain (CH-JL4) and another isolate (HRB-SS), with the recombination breakpoint located within the protease-polymerase (PP) region [20]. In Guangxi, China, dual recombination events were identified in strains of both respiratory and enteric origin, suggesting that enteric FCVs may serve as an important reservoir for genetic exchange with respiratory strains, thereby facilitating viral evolution and the emergence of new pathotypes [24]. These recombination events are not merely laboratory curiosities; they have been linked to the emergence of virulent strains, as demonstrated by a Korean study where a hemorrhagic-like disease-associated FCV (14Q315) was found to have undergone intergenic recombination between a Korean strain and the highly virulent UTCVM-H1 strain [36]. Such findings underscore the critical role of recombination in generating the genetic diversity that can lead to dramatic shifts in virulence and antigenicity.

Phylogenetic Classification and Genogroup Distribution

The genetic diversity of FCV has been systematically categorized through phylogenetic analysis, predominantly based on the sequence of the major capsid protein VP1, which is the primary target of neutralizing antibodies and a major determinant of antigenic variation [4, 14, 32]. This extensive body of work has established a consensus classification of FCV into two primary genogroups: GI and GII [5, 14, 23, 28, 30]. These genogroups are not merely arbitrary clusters; they represent distinct evolutionary lineages with demonstrable differences in geographical distribution and, potentially, antigenic properties.

Genogroup I (GI) is globally distributed and contains the majority of vaccine strains, including the widely used FCV-F9 strain and the FCV-255 strain [14, 43]. GI strains are found across Europe, the Americas, and Asia, and have historically been considered the predominant lineage. In contrast, Genogroup II (GII) exhibits a striking geographical restriction, with the vast majority of GII strains isolated exclusively from Asia, particularly China and Korea [5, 14, 23, 32]. This pattern suggests a more recent emergence or a specific ecological niche for GII in Asian feline populations. Studies in China have consistently documented a co-circulation of both GI and GII strains, with the relative prevalence varying by region and time period. For instance, in Kunshan, GII was found to be predominant [5], while in Nanjing, GI was more common [28], and in Guangdong, both genogroups were detected [23]. In contrast, a study of European isolates from six countries found no evidence of GII strains, supporting the hypothesis of its regional confinement to Asia [49]. The genetic divergence between the genogroups has practical implications. Analysis of VP1 sequences has revealed specific amino acid residues that are conserved within a genogroup but differ between GI and GII, which may serve as genogroup-specific markers [32]. Importantly, cross-neutralization studies have shown that antibodies raised against GI strains, including the commonly used vaccine strain FCV-255, are often less effective at neutralizing GII strains, suggesting that the emergence and spread of GII in Asia may be contributing to vaccine failures in that region [14, 26].

The phylogenetic landscape of FCV, however, is not static. Extensive studies have demonstrated a radial phylogenetic structure with little to no temporal or geographical clustering, meaning that strains isolated decades apart or from different continents can intermingle on a phylogenetic tree [2, 33, 43]. This pattern indicates that the virus does not evolve in a simple linear fashion over time and that multiple divergent lineages are circulating simultaneously within a single region. This lack of clear temporal or spatial signal is a hallmark of a virus that is constantly undergoing diversification and is not subject to strong, directional selective sweeps, at least at the population level. Furthermore, phylogenetic analyses have failed to establish a definitive genetic marker that can reliably distinguish classical upper respiratory tract (URTD) strains from highly virulent VS-FCV strains [21, 50]. Despite extensive sequencing of the VP1 gene, particularly the hypervariable E region, attempts to associate specific amino acid motifs with the VS-FCV pathotype have been largely unsuccessful. One study using Multiple Correspondence Analysis (MCA) of amino acid properties within region E did identify seven residue positions that showed statistical differences between VSD and classical strains, primarily in the N-terminal hypervariable part of region E [42]. However, these findings have not been universally replicated, and a subsequent in-depth analysis of Australian VS-FCV isolates found that the properties of residues in the hypervariable E region could not reliably differentiate between the two pathotypes [21]. This suggests that the molecular basis for the increased virulence of VS-FCV is likely multifactorial, involving not only the capsid but also non-structural proteins, such as the p30 protein, which has been shown to antagonize the type I interferon response more effectively in virulent strains [41].

Antigenic Variation and Immune Escape

The primary driver of antigenic variation in FCV is the genetic plasticity of the VP1 capsid protein. VP1 is organized into a shell (S) domain, a protruding (P) domain, and a flexible hinge region connecting them. The P domain is further subdivided into subdomains P1 and P2, with the P2 subdomain forming the outermost surface of the capsid and containing the hypervariable E region [8, 39]. This E region is the major target of neutralizing antibodies and is under intense selective pressure from the host immune system, leading to a remarkable degree of amino acid sequence diversity among field strains [4, 28, 33, 43]. The extensive variation within this region is the principal mechanism by which FCV evades pre-existing immunity, including that induced by vaccination.

The evolutionary consequence of this antigenic plasticity is profound. Studies have shown that the continued use of a single vaccine strain, FCV-F9, over several decades has not resulted in a progressive, directional antigenic drift of field viruses away from the vaccine strain, as is often observed with influenza virus [43]. Instead, FCV exhibits a pattern of "antigenic stasis" at the population level, where the neutralization profiles of field isolates do not show a consistent temporal trend. A landmark study comparing FCV isolates from the UK collected in 2001 and 2013/2014 found that FCV-F9 antisera remained broadly and equally cross-reactive to both populations, with no evidence of a progressive divergence [43]. This is likely because the immunodominant region of the VP1 capsid, while hypervariable, is subject to significant structural constraints related to its function in receptor binding (fJAM-A) and interactions with VP2, which limit the repertoire of viable antigenic changes. Critically, even though vaccine antisera remain broadly reactive in vitro, this does not translate into sterilizing immunity in vivo. Vaccinated cats can still become infected, shed virus, and develop clinical signs, albeit often with reduced severity [34, 62]. The high level of antigenic diversity among field strains means that the vaccine-induced antibody response may not be sufficiently high or broad to neutralize all circulating variants, allowing for breakthrough infections [33].

The functional importance of specific regions within VP1 has been characterized in detail. The E region (amino acids 426–520) is a linear neutralizing epitope, and amino acid substitutions in this region, particularly within a short motif (e.g., D434, G438, and a conserved Y437), are critical for the virus to escape neutralization by monoclonal antibodies (MAbs) [39]. Two distinct linear epitopes have been precisely mapped: a highly conserved, non-neutralizing epitope (PAGDY) at positions 431-435, and a hypervariable, neutralizing epitope (ITTANQY) at positions 445-451 [39]. The CDE region, which encompasses both the conserved C/D region and the hypervariable E region, has been identified as the dominant neutralizing epitope region and a promising candidate for subunit vaccine development, as it induces robust neutralizing antibody responses and provides protection against challenge [8, 55]. The CDE region's structural stability, conferred by hydrogen bonding interactions between the CD and E regions, makes it a practical target for recombinant protein production [8]. Furthermore, the identification of a strain (DL39) with broad-spectrum neutralization activity against both GI and GII strains highlights the potential to identify conserved epitopes within the hypervariable region that could be exploited for the development of broadly protective vaccines [14, 55].

The interaction of the capsid with the cellular receptor, feline junctional adhesion molecule-A (fJAM-A), is a highly conserved process. While the hypervariable E region is responsible for antibody binding, the receptor binding interface appears to be structurally constrained, and key residues involved in fJAM-A binding are highly conserved across diverse FCV strains [2]. This conservation is a double-edged sword: it ensures that all FCV strains use the same receptor for entry, but it also imposes functional constraints on the capsid structure, preventing the extreme antigenic drift that would otherwise render all vaccines useless.

The antigenic variation of FCV is not limited to the major capsid protein. The minor capsid protein VP2, while not a primary target of neutralizing antibodies, plays a critical role in genome release. Recent research has shown that VP2 functions as a pore-forming protein, puncturing the endosomal membrane to allow the viral RNA genome to enter the cytoplasm [6]. The N-terminus of VP2, which is rich in hydrophobic residues, is essential for this pore-forming activity, and mutations in this region reduce genome release efficacy [6]. While VP2 is not thought to be a significant target of antibody-mediated neutralization, its functional importance makes it a potential target for antiviral drugs that could interfere with the uncoating process.

In summary, the genetic diversity and antigenic variation of FCV are the defining features of this pathogen. They are driven by an error-prone polymerase and facilitated by recombination, resulting in a global population of highly diverse strains that are classified into two genogroups with distinct epidemiological patterns. The hypervariable E region of the VP1 capsid is the epicenter of antigenic variation, allowing FCV to evade immune pressure and persist in the face of widespread vaccination. Understanding the molecular basis of this variation, including the structural constraints that limit antigenic drift and the potential for identifying conserved neutralizing epitopes, is the key to developing more effective vaccines and diagnostics for this complex and challenging virus.

Prevention, Control, and Vaccination Strategies for Feline Calicivirus

Vaccination: The Cornerstone of FCV Prevention

Vaccination remains the most critical tool for mitigating the clinical impact of feline calicivirus (FCV) infection in domestic cat populations. However, the inherent genetic and antigenic plasticity of this single-stranded RNA virus presents profound and persistent challenges to the development of a universally protective vaccine. Current commercially available vaccines are classified as either modified-live virus (MLV) or inactivated (killed) products, and they are typically combined with antigens for feline herpesvirus-1 (FHV-1) and feline panleukopenia virus (FPV) in multivalent formulations, such as the FVRCP vaccine [5, 76]. The most widely used vaccine strains globally include FCV-F9, FCV-255, and strains 431 and G1, which were isolated decades ago [4, 14, 43, 64]. While these vaccines are effective at reducing the severity of clinical disease, they do not prevent infection, viral shedding, or the establishment of a carrier state, a limitation that has been consistently documented in both experimental and field studies [3, 34, 49]. The high mutation rate of FCV, particularly within the hypervariable E region of the major capsid protein VP1, which contains critical neutralizing antibody epitopes, drives the continuous emergence of antigenically distinct field strains that may escape vaccine-induced immunity [2, 9, 28, 32]. This phenomenon is not indicative of a systematic, long-term antigenic drift away from vaccine strains, as large-scale European cross-sectional studies have demonstrated that antisera raised against FCV-F9 remain broadly cross-reactive to contemporary field isolates, neutralizing up to 97% of tested strains [43, 49]. Rather, the issue is one of heterologous challenge: the vaccine strain induces a robust humoral response against itself, but this response may be suboptimal against a genetically diverse field strain encountered in practice, leading to breakthrough infections characterized by mild to moderate clinical signs [49, 62].

The immunological basis for vaccine-mediated protection extends beyond neutralizing antibodies. A seminal study by Spiri et al. (2021) using specified pathogen-free cats demonstrated that subcutaneous MLV vaccination (FCV-F9) induced a Th1-biased cellular immune response, characterized by the detection of IFN-γ-releasing peripheral blood mononuclear cells and upregulation of perforin and granzyme B mRNA transcription, even in the absence of detectable cross-neutralizing antibodies against the heterologous challenge virus [62]. This cellular immunity, alongside innate antiviral mechanisms like MX1, was associated with significantly reduced clinical scores, lower viral RNA loads in the oropharynx, and diminished RNAemia following challenge, compared to unvaccinated control cats [34, 62]. These findings underscore that protection against FCV is multifactorial, and that reliance solely on serological correlates of protection, such as virus neutralization titers against the vaccine strain, may underestimate the true protective capacity of a vaccinated animal [62, 64].

Despite these protective benefits, significant knowledge gaps and practical limitations persist. Vaccination frequency, route of administration, and the choice between MLV and inactivated products are subjects of ongoing debate. Inactivated vaccines, while considered safer for use in immunocompromised cats or pregnant queens, may induce a weaker and shorter-lived immune response compared to MLV vaccines, often requiring booster injections and adjuvants to enhance immunogenicity [4, 64]. However, concerns regarding vaccine-associated sarcomas have led to a preference for non-adjuvanted, modified-live products wherever appropriate [4]. A critical finding from field studies is that vaccination status is a significant risk factor for FCV infection, with vaccinated cats being less likely to test positive, yet a substantial proportion of FCV-positive cats have been vaccinated [2, 5, 9, 33]. This emphasizes that current vaccines are imperfect and that herd immunity is difficult to achieve given the high transmissibility and genetic diversity of the virus.

Novel Vaccine Platforms: The Quest for Broad-Spectrum Protection

The inadequacy of traditional vaccine strains in providing sterilizing immunity against the expanding spectrum of FCV genotypes, including the clinically devastating virulent systemic (VS-FCV) strains, has driven intensive research into next-generation vaccine platforms [3, 8, 18].

Subunit and Recombinant Protein Vaccines: A paradigm shift is underway with the identification of conserved, immunodominant regions within the VP1 capsid protein. The CDE region, which encompasses the E hypervariable domain stabilized by interactions with the C and D regions, has emerged as a promising target [8, 55]. Li et al. (2024) demonstrated that a recombinant CDE subunit vaccine, produced in E. coli, elicited significant humoral (IgG, IgA), mucosal, and cellular (CD4+ T cell, TNF-α) immune responses in cats [8]. Crucially, this vaccine significantly reduced disease incidence following viral challenge, offering a safer, cheaper, and more stable alternative to live vaccines [8]. Building on this, Yang et al. (2024) screened a panel of Chinese FCV isolates and identified strain DL39 (GI genotype) as possessing broad-spectrum neutralizing properties [14, 55]. They subsequently engineered a bivalent recombinant protein, CE39-CEFB, based on the optimal protective antigen region (CE region) from both GI and GII genotypes [55]. Cats immunized with this bivalent protein produced cross-neutralizing antisera against GI, GII, and VS-FCV strains, with superior neutralization titers compared to those induced by a commercial inactivated vaccine (strain 255) [55]. These findings represent a tangible step toward a vaccine capable of overcoming genotype-specific immunity.

Vectored Vaccines: A second innovative approach involves the use of a genetically modified viral vector, such as recombinant feline herpesvirus-1 (FHV-1). Tang et al. (2024) engineered a recombinant FHV-1 strain with deletions in the virulence-associated gI/gE genes, which simultaneously expressed the full-length FCV VP1 protein [72]. This bivalent vaccine, administered intranasally, was safe and induced robust immune responses in cats [72]. Upon heterologous FCV challenge, vaccinated animals exhibited significantly reduced clinical disease scores, pathological changes, and viral nasal shedding compared to controls [72]. This vectored platform offers the dual advantage of delivering immunogenic antigens from both major feline respiratory pathogens in a single dose, while also providing a favorable safety profile through the targeted attenuation of the vector [72].

Inactivated Vaccines from Circulating Strains: Recognizing the regional dominance of specific genotypes, Chinese researchers have pursued the development of autogenous or region-specific inactivated vaccines. Cao et al. (2023) isolated representative epidemic strains (FCV-HB7 and FCV-HB10) from China, which fell into distinct phylogenetic groups (C and D) distant from the commercial FCV-255 strain [18]. These strains exhibited high in vitro replication titers. A bivalent inactivated vaccine formulated from these two isolates induced significantly higher cross-neutralizing antibody titers against a panel of seven representative epidemic strains than the monovalent or commercial vaccines [18]. This strategy, while logistically more complex, highlights the importance of matching vaccine antigens to locally circulating field strains to maximize efficacy in specific geographic regions [5, 23, 28].

Biosecurity and Environmental Control: Breaking the Chain of Transmission

Given the limitations of vaccination in preventing infection and shedding, meticulous biosecurity practices are essential for controlling FCV, particularly in high-density environments such as shelters, breeding catteries, and veterinary hospitals [3, 7, 11, 22]. FCV is a remarkably hardy, non-enveloped virus that can persist in the environment for weeks to months, surviving on surfaces, food bowls, bedding, and even cat hair [45, 46]. Transmission occurs primarily through direct contact with infected saliva, nasal secretions, and ocular discharge, as well as indirectly via fomites and aerosolized droplets over short distances [3, 45].

Disinfection Protocols: Effective decontamination requires the use of disinfectants with proven virucidal activity against non-enveloped viruses. Sodium hypochlorite (bleach) at a 1:32 dilution (0.5% sodium hypochlorite) is a gold standard, but it is corrosive and can be inactivated by organic matter. As an alternative, 5% sodium bicarbonate has been shown to be effective for environmental disinfection in research settings, with no detectable viral RNA found outside treated cat rooms after its use [45]. Accelerated hydrogen peroxide (e.g., 7.5% solutions) delivered via fogging systems has demonstrated potent virucidal activity, achieving over 4-log₁₀ reduction of infectious FCV on stainless steel surfaces within 5 minutes [70]. This method is particularly advantageous for reaching difficult-to-access surfaces and for terminal disinfection of rooms following an outbreak [70]. Ultraviolet-C (UV-C) radiation, particularly at 254 nm, is another highly effective non-chemical method. UV-C at a dose of approximately 24.6 mJ/cm² can achieve a greater than 4-log₁₀ reduction of FCV on hard surfaces, with the D₁₀ value (dose required for 90% inactivation) ranging from 3.65 to 6.25 mJ/cm² depending on the surface [10]. Novel UV-C LED systems at 279 nm are also effective, though they require higher doses, offering a user-friendly, toxic-free alternative [10]. Aqueous ozone at approximately 1 ppm can inactivate FCV by over 6-log PFU/mL within 5 minutes in low-organic matter water, though efficacy is reduced in high-organic load conditions [19].

Isolation and Barrier Nursing: The capacity for FCV to cause devastating nosocomial outbreaks of virulent systemic disease (VS-FCV) with mortality rates exceeding 70% underscores the absolute necessity for strict isolation protocols [7, 11]. Any cat presenting with pyrexia of unknown origin, limb edema, or cutaneous ulceration, especially with a history of exposure to rescue cats, should be immediately placed in strict isolation until VS-FCV is ruled out [7, 11]. During outbreaks, a "traffic flow" approach should be implemented: staff should attend to healthy or low-risk animals first, followed by suspect cases, and finally confirmed FCV-positive cases. Dedicated footwear, gowns, and gloves should be used for each isolation unit, and hand hygiene with either soap and water or alcohol-based sanitizers (though these may be less effective against non-enveloped viruses) is critical [45]. The high environmental stability of FCV RNA, which can be detected by RT-qPCR for at least 28 days after shedding ceases, means that negative RT-qPCR results from environmental swabs do not necessarily confirm the absence of infectious virus [45]. Therefore, a combination of thorough cleaning, disinfection, and a minimum quarantine period of 7–14 days following resolution of clinical signs in the last affected animal is recommended before repopulating a contaminated area [7].

Antiviral and Immunomodulatory Strategies: A Developing Frontier

While supportive care remains the mainstay of treatment for FCV infections, the emergence of VS-FCV has intensified the search for specific antiviral agents. Currently, no direct-acting antiviral is approved for veterinary use against FCV, a significant gap that leaves clinicians with few options for severe or refractory cases [3, 21, 75].

Direct-Acting Antivirals: In vitro and in vivo studies have identified several promising candidates. Nitazoxanide (NTZ), a thiazolide anti-infective, has shown potent antiviral activity against multiple FCV strains, with EC₅₀ values in the low micromolar range (0.4–0.6 μM) and a favorable therapeutic index [21, 69, 75]. In a feline challenge model, oral administration of NTZ significantly reduced clinical signs, decreased viral load in the trachea and lungs, and suppressed viral shedding [69]. Furthermore, NTZ has demonstrated synergy with mizoribine, an immunosuppressive agent, suggesting potential for combination therapy to enhance efficacy and reduce the risk of resistance [69]. The nucleoside analogue 2′-C-methylcytidine (2CMC) also exhibits potent in vitro activity against FCV (EC₅₀ 2.5–5.3 μM), including virulent systemic strains, by inhibiting viral RNA-dependent RNA polymerase [21, 75]. The broad-spectrum antiviral NITD-008, a nucleoside analogue targeting flaviviruses, has also shown activity against FCV-VSD strains (EC₅₀ 0.5–0.9 μM) with a remarkably high therapeutic index [21]. While these compounds are not yet commercially available for feline use, they represent a critical pipeline for future therapeutic interventions.

Immune-Based and Immunomodulatory Therapies: Passive immunotherapy with equine-derived F(ab')₂ fragments has demonstrated prophylactic and therapeutic efficacy [74]. Cats receiving anti-FCV F(ab')₂ fragments showed significantly reduced clinical signs and lower viral loads in the trachea and lungs compared to controls, suggesting that this approach could be valuable for outbreak management or for protecting high-risk individuals [74]. Feline recombinant interferon-omega (rFeIFN-ω), administered subcutaneously at 1 MU/kg, has been shown to reduce viral loads and improve clinical scores in cats with FCV-associated chronic gingivostomatitis, likely through both direct antiviral and immunomodulatory effects [71]. However, the efficacy of this approach is variable and may be strain-dependent [71]. The role of autophagy in FCV pathogenesis is also being explored; FCV non-structural proteins P30, P32, and P39 trigger autophagy, which suppresses the RIG-I innate immune pathway [16]. Compounds that modulate autophagy are being investigated as potential host-directed antivirals [16]. Additionally, the MEK1-ERK1/2 signaling pathway is exploited by FCV to induce COX-2 production, and the MEK1 inhibitor AZD6244 (selumetinib) has shown promise in a kitten model by suppressing lung inflammation and injury, normalizing body temperature, and reducing IL-6 levels [73]. These immunomodulatory approaches offer a complementary strategy to direct-acting antivirals, potentially reducing the pathological consequences of infection even if viral replication is not completely ablated.

References

[1] Wang H, Xue L, Wang L, Liu Y, Chen J, Sun Y, et al.. The quadruplex TaqMan MGB fluorescent quantitative PCR method for simultaneous detection of feline panleukopenia virus, feline herpesvirus 1, feline calicivirus and feline infectious peritonitis virus. Frontiers in Cellular and Infection Microbiology. 2025. DOI: https://doi.org/10.3389/fcimb.2025.1581946

[2] Wang D, Zhu J, Yang H, Lyu Y. Epidemiology and Molecular Characterization of Feline Calicivirus in Beijing, China. Animals. 2025. DOI: https://doi.org/10.3390/ani15040494

[3] Profio FD, Carnevale M, Marsilio F, Pellegrini F, Martella V, Martino BD, et al.. Feline Calicivirus Infection: Current Understanding and Implications for Control Strategies. Animals. 2025. DOI: https://doi.org/10.3390/ani15142009

[4] Wei Y, Zeng Q, Gou H, Bao S. Update on feline calicivirus: viral evolution, pathogenesis, epidemiology, prevention and control. Frontiers in Microbiology. 2024. DOI: https://doi.org/10.3389/fmicb.2024.1388420

[5] Kim S, Cheng Y, Fang Z, Liu X, Qiu Z, Yu W, et al.. Molecular epidemiology and phylogenetic analysis of feline calicivirus in Kunshan, China. Virology Journal. 2024. DOI: https://doi.org/10.1186/s12985-024-02319-9

[6] Sun W, Wang M, Shi Z, Wang P, Wang J, Du B, et al.. VP2 mediates the release of the feline calicivirus RNA genome by puncturing the endosome membrane of infected cells. Journal of Virology. 2024. DOI: https://doi.org/10.1128/jvi.00350-24

[7] Park J, Lee D, Hong Y, Hwang C, Hyun J. Outbreaks of nosocomial feline calicivirus-associated virulent systemic disease in Korea. Journal of Veterinary Sciences. 2024. DOI: https://doi.org/10.4142/jvs.24030

[8] Li L, Liu Z, Shi J, Yang M, Yan Y, Fu Y, et al.. The CDE region of feline Calicivirus VP1 protein is a potential candidate subunit vaccine. BMC Veterinary Research. 2024. DOI: https://doi.org/10.1186/s12917-024-03914-2

[9] Phongroop K, Rattanasrisomporn J, Piewbang C, Tangtrongsup S, Rungsipipat A, Techangamsuwan S. Molecular epidemiology and strain diversity of circulating feline Calicivirus in Thai cats. Frontiers in Veterinary Science. 2024. DOI: https://doi.org/10.3389/fvets.2024.1377327

[10] Polen B, Pendyala B, Patras A, D'Souza D. Inactivation of Hepatitis A Virus and Feline Calicivirus on Model Food Contact Surfaces by Ultraviolet Light (UV-C) Systems. Foods. 2024. DOI: https://doi.org/10.3390/foods13182892

[11] Duclos A, Ramos PJG, Mooney CT. Virulent systemic feline calicivirus infection: a case report and first description in Ireland. Irish Veterinary Journal. 2024. DOI: https://doi.org/10.1186/s13620-024-00262-3

[12] Lanave G, Catella C, Catalano A, Lucente M, Pellegrini F, Fracchiolla G, et al.. Assessing the virucidal activity of essential oils against feline calicivirus, a non-enveloped virus used as surrogate of norovirus. Heliyon. 2024. DOI: https://doi.org/10.1016/j.heliyon.2024.e30492

[13] Pellegrini F, Camero M, Catella C, Fracchiolla G, Sblano S, Patruno G, et al.. Virucidal Activity of Lemon Essential Oil against Feline Calicivirus Used as Surrogate for Norovirus. Antibiotics. 2023. DOI: https://doi.org/10.3390/antibiotics12020322

[14] Yang Y, Liu Z, Chen M, Feng K, Qi R, Zheng Y, et al.. Classification of genotypes based on the VP1 gene of feline calicivirus and study of cross-protection between different genotypes. Frontiers in Microbiology. 2023. DOI: https://doi.org/10.3389/fmicb.2023.1226877

[15] Lanave G, Buonavoglia A, Pellegrini F, Martino BD, Profio FD, Diakoudi G, et al.. An Outbreak of Limping Syndrome Associated with Feline Calicivirus. Animals. 2023. DOI: https://doi.org/10.3390/ani13111778

[16] Mao J, Ye S, Deng J, Song J, Wang Z, Chen A, et al.. Feline Calicivirus P39 Inhibits Innate Immune Responses by Autophagic Degradation of Retinoic Acid Inducible Gene I. International Journal of Molecular Sciences. 2023. DOI: https://doi.org/10.3390/ijms24065254

[17] Fontes AC, Vieira MC, Oliveira M, Lourenço L, Viegas C, Faísca P, et al.. Feline calicivirus and natural killer cells: A study of its relationship in chronic gingivostomatitis. Veterinary World. 2023. DOI: https://doi.org/10.14202/vetworld.2023.1708-1713

[18] Cao L, Liu J, Li Y, Xie D, Yan Q, Li Q, et al.. Biological Characteristics of Feline Calicivirus Epidemic Strains in China and Screening of Broad-Spectrum Protective Vaccine Strains. Vaccines. 2023. DOI: https://doi.org/10.3390/vaccines11121858

[19] Choi J, D'Souza D. Inactivation of Tulane virus and feline calicivirus by aqueous ozone.. Journal of Food Science. 2023. DOI: https://doi.org/10.1111/1750-3841.16755

[20] Liu Y, Qin L, Hu X, Jiang Y. Isolation and molecular characteristics of a recombinant feline calicivirus from Qingdao, China. Veterinary Research Forum. 2023. DOI: https://doi.org/10.30466/vrf.2023.1975795.3701

[21] Bordicchia M, Fumian T, Brussel KV, Russo AG, Carrai M, Le S, et al.. Feline Calicivirus Virulent Systemic Disease: Clinical Epidemiology, Analysis of Viral Isolates and In Vitro Efficacy of Novel Antivirals in Australian Outbreaks. Viruses. 2021. DOI: https://doi.org/10.3390/v13102040

[22] Spiri A. An Update on Feline Calicivirus.. Schweizer Archiv für Tierheilkunde. 2022. DOI: https://doi.org/10.17236/sat00346

[23] Mao J, Ye S, Li Q, Bai Y, Wu J, Xu L, et al.. Molecular Characterization and Phylogenetic Analysis of Feline Calicivirus Isolated in Guangdong Province, China from 2018 to 2022. Viruses. 2022. DOI: https://doi.org/10.3390/v14112421

[24] Guo J, Ding Y, Sun F, Zhou H, He P, Chen J, et al.. Co‐circulation and evolution of genogroups I and II of respiratory and enteric feline calicivirus isolates in cats. Transboundary and Emerging Diseases. 2022. DOI: https://doi.org/10.1111/tbed.14447

[25] Palombieri A, Sarchese V, Giordano MV, Fruci P, Crisi P, Aste G, et al.. Detection and Characterization of Feline Calicivirus Associated with Paw and Mouth Disease. Animals. 2022. DOI: https://doi.org/10.3390/ani13010065

[26] Zhou L, Fu N, Ding L, Li Y, Huang J, Sha X, et al.. Molecular Characterization and Cross-Reactivity of Feline Calicivirus Circulating in Southwestern China. Viruses. 2021. DOI: https://doi.org/10.3390/v13091812

[27] Peñaflor-Téllez Y, Chávez-Munguía B, Lagunes-Guillén A, Salazar-Villatoro L, Gutiérrez-Escolano A. The Feline Calicivirus Leader of the Capsid Protein Has the Functional Characteristics of a Viroporin. Viruses. 2022. DOI: https://doi.org/10.3390/v14030635

[28] Liang J, Zang M, Zhou Z. Genetic and phylogenetic analysis of capsid gene of feline calicivirus in Nanjing, China.. Infection, Genetics and Evolution. 2022. DOI: https://doi.org/10.1016/j.meegid.2022.105323

[29] Balboni A, Verin R, Buldrini I, Zamagni S, Morini M, Terrusi A, et al.. Natural cases of polyarthritis associated with feline calicivirus infection in cats. Veterinary research communications. 2022. DOI: https://doi.org/10.1007/s11259-022-09933-4

[30] Komina A, Krasnikov N, Kucheruk O, Zhukova E, Yuzhakov A, Gulyukin A. Distribution and genetic diversity of Feline calicivirus in Moscow metropolitan area. Journal of Veterinary Sciences. 2022. DOI: https://doi.org/10.4142/jvs.22182

[31] Fried W, Soltero-Rivera M, Ramesh A, Lommer M, Arzi B, Derisi J, et al.. Use of unbiased metagenomic and transcriptomic analyses to investigate the association between feline calicivirus and feline chronic gingivostomatitis in domestic cats.. American Journal of Veterinary Research. 2021. DOI: https://doi.org/10.2460/ajvr.82.5.381

[32] Cao L, Li Q, Shi K, Wei L, Ouyang H, Ye Z, et al.. Isolation and phylogenetic analysis of feline calicivirus strains from various region of China. Animal Diseases. 2022. DOI: https://doi.org/10.1186/s44149-022-00047-7

[33] Zheng M, Li Z, Fu X, Lv Q, Yang Y, Shi F. Prevalence of feline calicivirus and the distribution of serum neutralizing antibody against isolate strains in cats of Hangzhou, China. Journal of Veterinary Sciences. 2021. DOI: https://doi.org/10.4142/jvs.2021.22.e73

[34] Spiri A, Riond B, Stirn M, Novacco M, Meli M, Boretti F, et al.. Modified-Live Feline Calicivirus Vaccination Reduces Viral RNA Loads, Duration of RNAemia, and the Severity of Clinical Signs after Heterologous Feline Calicivirus Challenge. Viruses. 2021. DOI: https://doi.org/10.3390/v13081505

[35] Wang Z. feline calicivirus. CABI Compendium. 2022. DOI: https://doi.org/10.1201/b19719-16

[36] Lee S, Kim Y, Kim Y, Na E, Kim Y, Oem J. Intergenic recombination in feline calicivirus associated with a hemorrhagic-like disease in the Republic of Korea.. Acta virologica. 2021. DOI: https://doi.org/10.4149/av_2021_206

[37] Wu H, Huang J, Liu Y, Pan Y, Li Y, Miao Q, et al.. Feline Calicivirus Proteinase-Polymerase Protein Degrades mRNAs To Inhibit Host Gene Expression. Journal of Virology. 2021. DOI: https://doi.org/10.1128/JVI.00336-21

[38] Martino BD, Lanave G, Profio FD, Melegari I, Marsilio F, Camero M, et al.. Identification of feline calicivirus in cats with enteritis.. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13605

[39] Cubillos-Zapata C, Angulo I, Almanza H, Borrego B, Zamora-Ceballos M, Castón JR, et al.. Precise location of linear epitopes on the capsid surface of feline calicivirus recognized by neutralizing and non-neutralizing monoclonal antibodies. Veterinary Research. 2020. DOI: https://doi.org/10.1186/s13567-020-00785-x

[40] Kratzer G, Lewis F, Willi B, Meli M, Boretti F, Hofmann-Lehmann R, et al.. Bayesian Network Modeling Applied to Feline Calicivirus Infection Among Cats in Switzerland. Frontiers in Veterinary Science. 2020. DOI: https://doi.org/10.3389/fvets.2020.00073

[41] Tian J, Kang H, Huang J, Li Z, Pan Y, Li Y, et al.. Feline calicivirus strain 2280 p30 antagonizes type I interferon-mediated antiviral innate immunity through directly degrading IFNAR1 mRNA. PLoS Pathogens. 2020. DOI: https://doi.org/10.1371/journal.ppat.1008944

[42] Brunet S, Sigoillot-Claude C, Pialot D, Poulet H. Multiple Correspondence Analysis on Amino Acid Properties within the Variable Region of the Capsid Protein Shows Differences between Classical and Virulent Systemic Feline Calicivirus Strains. Viruses. 2019. DOI: https://doi.org/10.3390/v11121090

[43] Smith SL, Afonso MM, Pinchbeck G, Gaskell R, Dawson S, Radford A. Temporally separated feline calicivirus isolates do not cluster phylogenetically and are similarly neutralised by high-titre vaccine strain FCV-F9 antisera in vitro. Journal of feline medicine and surgery. 2019. DOI: https://doi.org/10.1177/1098612X19866521

[44] Barrera-Vázquez O, Cancio-Lonches C, Hernández-González O, Chávez-Munguía B, Villegas-Sepúlveda N, Gutiérrez-Escolano A. The feline calicivirus leader of the capsid protein causes survivin and XIAP downregulation and apoptosis.. Virology. 2019. DOI: https://doi.org/10.1016/j.virol.2018.11.017

[45] Spiri A, Meli M, Riond B, Herbert I, Hosie M, Hofmann-Lehmann R. Environmental Contamination and Hygienic Measures After Feline Calicivirus Field Strain Infections of Cats in a Research Facility. Viruses. 2019. DOI: https://doi.org/10.3390/v11100958

[46] Urban C, Luttermann C. Major Capsid Protein Synthesis from the Genomic RNA of Feline Calicivirus. Journal of Virology. 2020. DOI: https://doi.org/10.1128/JVI.00280-20

[47] Guo H, Miao Q, Zhu J, Yang Z, Liu G. Isolation and molecular characterization of a virulent systemic feline calicivirus isolated in China.. Infection, Genetics and Evolution. 2018. DOI: https://doi.org/10.1016/j.meegid.2018.08.029

[48] Druet IMC, Hennet P. Relationship between Feline calicivirus Load, Oral Lesions, and Outcome in Feline Chronic Gingivostomatitis (Caudal Stomatitis): Retrospective Study in 104 Cats. Frontiers in Veterinary Science. 2017. DOI: https://doi.org/10.3389/fvets.2017.00209

[49] Afonso MM, Pinchbeck G, Smith SL, Daly J, Gaskell R, Dawson S, et al.. A multi-national European cross-sectional study of feline calicivirus epidemiology, diversity and vaccine cross-reactivity.. Vaccine. 2017. DOI: https://doi.org/10.1016/j.vaccine.2017.03.030

[50] Caringella F, Elia G, Decaro N, Martella V, Lanave G, Varello K, et al.. Feline calicivirus infection in cats with virulent systemic disease, Italy.. Research in Veterinary Science. 2019. DOI: https://doi.org/10.1016/j.rvsc.2019.02.008

[51] Santos-Valencia JC, Cancio-Lonches C, Trujillo-Uscanga A, Alvarado-Hernández B, Lagunes-Guillén A, Gutiérrez-Escolano A. Annexin A2 associates to feline calicivirus RNA in the replication complexes from infected cells and participates in an efficient viral replication.. Virus Research. 2019. DOI: https://doi.org/10.1016/j.virusres.2018.12.003

[52] Liu Y, Liu X, Kang H, Hu X, Liu J, Tian J, et al.. Identification of Feline Interferon Regulatory Factor 1 as an Efficient Antiviral Factor against the Replication of Feline Calicivirus and Other Feline Viruses. BioMed Research International. 2018. DOI: https://doi.org/10.1155/2018/2739830

[53] jiang F, Liu Y, Yang X, Li Y, Huang J. Ultrasensitive and visual detection of Feline herpesvirus type-1 and Feline calicivirus using one-tube dRPA-Cas12a/Cas13a assay. BMC Veterinary Research. 2024. DOI: https://doi.org/10.1186/s12917-024-03953-9

[54] Zhang Z, Li J, Zhang C, Bai X, Zhang T. Rapid Detection of Feline Calicivirus Using Lateral Flow Dipsticks Based on CRISPR/Cas13a System. Animals. 2024. DOI: https://doi.org/10.3390/ani14243663

[55] Yang Y, Qi R, Chen M, Feng K, Liu Z, Kang H, et al.. Screening and Immune Efficacy Evaluation of Antigens with Protection Against Feline Calicivirus. Vaccines. 2024. DOI: https://doi.org/10.3390/vaccines12111205

[56] Chen B, Zhang H, Wang H, Li S, Zhou P. Development and application of a dual ERA method for the detection of Feline Calicivirus and Feline Herpesvirus Type I. Virology Journal. 2023. DOI: https://doi.org/10.1186/s12985-023-02020-3

[57] Cao N, Tang Z, Zhang X, Li W, Li B, Tian Y, et al.. Development and Application of a Triplex TaqMan Quantitative Real-Time PCR Assay for Simultaneous Detection of Feline Calicivirus, Feline Parvovirus, and Feline Herpesvirus 1. Frontiers in Veterinary Science. 2022. DOI: https://doi.org/10.3389/fvets.2021.792322

[58] Ye J, Li Z, Sun F, Guo L, Feng E, Bai X, et al.. Development of a triple NanoPCR method for feline calicivirus, feline panleukopenia syndrome virus, and feline herpesvirus type I virus. BMC Veterinary Research. 2022. DOI: https://doi.org/10.1186/s12917-022-03460-9

[59] Huang J, Liu Y, He Y, Yang X, Li Y. CRISPR-Cas13a Based Visual Detection Assays for Feline Calicivirus Circulating in Southwest China. Frontiers in Veterinary Science. 2022. DOI: https://doi.org/10.3389/fvets.2022.913780

[60] Hamdan A, Al-Baroodi S. Molecular investigation of feline calicivirus in cats in Mosul city, Iraq. Iraqi Journal of Veterinary Sciences. 2022. DOI: https://doi.org/10.33899/ijvs.2022.131706.1993

[61] Hermawan IP, Leo DM. Feline Calicivirus Infection with Chronic Stomatitis, Rhinitis and Otitis in a Bengal Cat in Indonesia. Veterinary Biomedical and Clinical Journal. 2022. DOI: https://doi.org/10.21776/ub.vetbioclinj.2022.004.02.1

[62] Spiri A, Novacco M, Meli M, Stirn M, Riond B, Fogle J, et al.. Modified-Live Feline Calicivirus Vaccination Elicits Cellular Immunity against a Current Feline Calicivirus Field Strain in an Experimental Feline Challenge Study. Viruses. 2021. DOI: https://doi.org/10.3390/v13091736

[63] Kim SJ, Park Y, Park K. Development of a novel reverse transcription PCR and its application to field sample testing for feline calicivirus prevalence in healthy stray cats in Korea. Journal of Veterinary Sciences. 2020. DOI: https://doi.org/10.4142/jvs.2020.21.e71

[64] Bergmann M, Speck S, Rieger A, Truyen U, Hartmann K. Antibody Response to Feline Calicivirus Vaccination in Healthy Adult Cats. Viruses. 2019. DOI: https://doi.org/10.3390/v11080702

[65] Pereira JdJ, Baumworcel N, Fioretti JM, Domingues CF, Moraes Ld, Marinho RdSS, et al.. Molecular characterization of feline calicivirus variants from multicat household and public animal shelter in Rio de Janeiro, Brazil. Brazilian Journal of Microbiology. 2018. DOI: https://doi.org/10.1016/j.bjm.2018.01.003

[66] Yan M, Shang J, Zhang X, Wu S, Wang C, Wang Z, et al.. The establishment and application of a dual Nano-PCR detection method for feline calicivirus and feline herpesvirus type I. Frontiers in Microbiology. 2023. DOI: https://doi.org/10.3389/fmicb.2023.1285268

[67] Khamsingnok P, Rapichai W, Rattanasrisomporn A, Rungsuriyawiboon O, Choowongkomon K, Rattanasrisomporn J. Comparison of PCR, Nested PCR, and RT-LAMP for Rapid Detection of Feline Calicivirus Infection in Clinical Samples. Animals. 2024. DOI: https://doi.org/10.3390/ani14162432

[68] Phongroop K, Rattanasrisomporn J, Tangtrongsup S, Rungsipipat A, Piewbang C, Techangamsuwan S. High-resolution melting analysis for simultaneous detection and discrimination between wild-type and vaccine strains of feline calicivirus. Veterinary Quarterly. 2023. DOI: https://doi.org/10.1080/01652176.2023.2272188

[69] . Nitazoxanide protects cats from feline calicivirus infection and acts synergistically with mizoribine in vitro. Antiviral Research. 2020. DOI: https://doi.org/10.1016/j.antiviral.2020.104827

[70] Montazeri N, Manuel C, Moorman E, Khatiwada J, Williams L, Jaykus L. Virucidal Activity of Fogged Chlorine Dioxide- and Hydrogen Peroxide-Based Disinfectants against Human Norovirus and Its Surrogate, Feline Calicivirus, on Hard-to-Reach Surfaces. Frontiers in Microbiology. 2017. DOI: https://doi.org/10.3389/fmicb.2017.01031

[71] Matsumoto H, Teshima T, Iizuka Y, Sakusabe A, Takahashi D, Amimoto A, et al.. Evaluation of the efficacy of the subcutaneous low recombinant feline interferon-omega administration protocol for feline chronic gingivitis-stomatitis in feline calicivirus-positive cats.. Research in Veterinary Science. 2018. DOI: https://doi.org/10.1016/j.rvsc.2018.10.003

[72] Tang A, Zhu M, Zhu J, Zhang D, Zhu S, Meng C, et al.. The recombinant feline herpesvirus 1 expressing feline Calicivirus VP1 protein is safe and effective in cats.. Vaccine. 2024. DOI: https://doi.org/10.1016/j.vaccine.2024.126468

[73] Liu Y, Shi W, Xie Q, Wang J, Gu C, Ji Z, et al.. Induction of COX-2 by feline calicivirus via activation of the MEK1-ERK1/2 pathway, and attenuation of feline lung inflammation and injury by MEK1 inhibitor AZD6244 (selumetinib).. Biochemical and Biophysical Research Communications - BBRC. 2022. DOI: https://doi.org/10.1016/j.bbrc.2022.02.060

[74] Cui Z, Li D, Yi S, Guo Y, Dong G, Niu J, et al.. Equine immunoglobulin F(ab')2 fragments protect cats against feline calicivirus infection. International Immunopharmacology. 2019. DOI: https://doi.org/10.1016/j.intimp.2019.105714

[75] Fumian T, Tuipulotu DE, Netzler NE, Lun J, Russo AG, Yan GJH, et al.. Potential Therapeutic Agents for Feline Calicivirus Infection. Viruses. 2018. DOI: https://doi.org/10.3390/v10080433

[76] Songaksorn N, Petsophonsakul W, Pringproa K, Lampang KN, Sthitmatee N, Srifawattana N, et al.. Prevalence of autoantibodies that bind to kidney tissues in cats and association risk with antibodies to feline viral rhinotracheitis, calicivirus, and panleukopenia. Journal of Veterinary Sciences. 2021. DOI: https://doi.org/10.4142/jvs.2021.22.e38